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ABSTRACT 
 
Alemrayat, Bayan F.  Masters:  January: 2017,  Pharmacy . 
Title: Production of Letrozole-Loaded Monodisperse Polymeric-Based Microparticles for Breast 
Cancer Therapy. 
Supervisor of Thesis: Dr. Husam M Younes. 
 
Letrozole (LTZ) is effective for the treatment of hormone-receptor-positive breast cancer 
in postmenopausal women. However, due to its adverse effects this study was designed to 
investigate the feasibility of producing monodisperse LTZ microparticles using either 
Poly-ε-Caprolactone (PCL) or Poly (D,L-Lactide) (PDLLA) as polymeric carriers to 
improve its release and safety profiles. An amount of 1 g PCL or PDLLA was mixed with 
5-30% w/w LTZ in 1-2 % w/v ml dichloromethane. Using Vibrating Orifice Aerosol 
Generator (VOAG) with a 300-µm orifice at a rate of 0.17-1.7 ml/min, and a frequency of 
100-1000 KHz, a constant stream of monodisperse microdroplets was generated. These 
droplets were collected in a 0.04-1% Polyvinyl Alcohol (PVA) aqueous medium and 
stirred at 250-500 rpm for 24 hours. Solidified microparticles were collected through 
filtration and dried under vacuum over 48 hours. Optimized microparticles were 
characterized for yield, morphology, particle size, entrapment efficiency, thermal and 
structural properties, in vitro release profile, and in vitro cytotoxicity evaluation using 
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4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) staining. Monodisperse 
microparticles were prepared with a high yield that ranged from 88.2-96.1%. Particles 
appeared to be spherical with smooth surfaces in both carriers. The particle size varied 
from 15.6 µm to 91.6 µm and from 22.7 µm to 99.6 µm with a span ranging from 0.22 to 
1.24 and from 0.29 to 1.48 in PCL- and PDLLA-based formulations, respectively. Liquid 
flow rate and PVA concentration were the main contributors to the variation in particle 
size. Upon optimizing the production parameters, span was reduced to 0.162-0.195. High 
entrapment efficiency was obtained reaching up to 96.8%. LTZ became completely 
amorphous at 5-10% w/w drug loading using PDLLA, and at all loadings using PCL. 
Drug release from PDLLA and PCL followed a biphasic zero-order release over 31 days 
using 5% and 30% w/w drug loadings. In vitro cytotoxicity results have shown that all 
LZT-PDLLA/PCL formulations significantly inhibited the growth of MCF-7 cell line at 
low concentrations reaching 10 nM, suggesting its potential clinical importance in 
suppressing breast tumor growth and invasiveness. This study indicated the potential of 
manufacturing new LTZ formulations for monthly administration as intramuscular 
injections (IM) which offer better release profiles that may result in minimal adverse 
effects. 
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Chapter 1: Introduction  
1.1 Breast Cancer 
 
1.1.1 Epidemiology      
 
Breast cancer is a life-threating disease that is highly common in women across the globe 
(1). It lies on top of the most prevalent types of cancer and it is considered the primary 
reason for cancer-related mortality (2), with nearly 1.68 million incidents and more than 
half a million deaths being documented worldwide in 2012 (3). Over 231,000 new cases 
of invasive breast cancer were diagnosed in USA in 2015 alone (4). In United Kingdom, 
more than 60,000 women are diagnosed with breast cancer annually (5). By itself, the 
disease makes up 25% of all cancers recorded and 15% of all human losses due to cancer 
among women universally (6). Although the disease prevalence is higher in developed 
countries, three quarters of the worldwide disease-associated deaths are arising from 
developing countries (7,8).  
In the Middle East, breast cancer is identified as the most widely spread cancer among 
females (9). Alarming figures indicate that the disease continues to affect more and more 
women in the region starting from the early 1980s; the majority of which are sadly in 
their 30s and 40s, and a significant percentage presenting with late disease stages (10). 
From a local perspective, breast cancer constitutes to be the number one diagnosed cancer 
in Qatar among women and both genders as well. According to Bener et al., a dramatic 
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increase of roughly 52.8% in the total new cases of breast cancer have been recorded in 
just 15-year period; from early 1990s to 2006 (11). In 2007 alone, breast cancer has 
accounted for approximately 20% of all treated cancers in National Center for Cancer 
Care and Research (NCCR) hospital (11). Overall incidence rate of breast cancer has 
been estimated to be 38.1 per 100,000 women, placing the country third in terms of breast 
cancer prevalence in the Middle East region (12). Recent reports from the World Health 
Organization (WHO) have highlighted that breast cancer is not only residing on top of 
detected cancers in Qatar, but also holds the highest mortality rates as compared to all 
other types with 12.9 deaths per 100,000 patients (13,14). Such finding reflects an 
extremely poor disease prognosis to be drawn in Qatar. 
 
1.1.2 Pathophysiology  
 
Multiple complex pathological transformations at the cellular level underlie the 
emergence of cancer (15–18). These primarily involve the mutation of certain genes that 
are responsible for the commencement or suppression of cell cycle. Such events result in 
uncontrollable cell proliferation, leading to the formation of neoplastic clusters. In breast 
cancer, particularly, the mutation of certain tumor suppressor genes such as phosphatase 
and tensin homolog (PTEN), tumor protein p53 (TP53), and breast cancer genes 1 and 2 
(BRCA1 and BRCA2) along with the overexpression of an oncogene called human 
epidermal growth factor receptor 2 (HER2) have been implicated in the predisposition of 
the disease (19–24). Mutations in BRCA1 and BRCA2 are thought to hold the highest 
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risk for developing cancerous manifestations within breast tissues (25–27). It has been 
estimated that women with this type of mutation carry a higher probability of developing 
breast cancer that reaches 40-60% as compared with those who do not have such 
mutation (28,29). Moreover, women who have been exposed to estrogen for prolonged 
period of time, whether endogenously or exogenously through hormonal supplements, are 
also more susceptible to develop breast cancers than others (30–33). Estrogen actually 
plays a significant role in triggering breast cancer as it binds to its receptor (ER) in the 
epithelial lining of breast tissues, prompting a cascade of cellular growth and 
proliferation. Progesterone binding to its receptor (PR) comes second to estrogen binding 
in terms of its importance in the development of breast cancer. In general, hormone 
receptor-positive breast cancers are widely common, accounting for roughly 50-70% of 
all breast cancer cases (34–36). Therefore, hormonal therapy is considered essential in the 
treatment of breast cancer most of the time.  
Classification of breast cancer depends predominantly on the histological and biological 
characteristics of epithelial cells. Tumors that are localized to the site of origin are termed 
in-situ tumors. On the other hand, tumors invading the surrounding tissues, spreading to 
other regions of the body are termed invasive or metastatic tumors. In essence, invasive 
tumors/metastasis have poorer prognosis and more severe clinical presentation compared 
to in-situ tumors (37–40). However, pharmacological advancements have brought 
promising solutions to manage invasive breast cancer and prolong the expected lifetime 
span of patients suffering from such devastating disease (41).         
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1.1.3 Treatment Strategies   
 
A number of pharmacological therapies are now available for the treatment and 
management of breast cancer. Based on the disease stage and other prognostic factors 
such as the activation of hormonal receptors, the therapeutic regimen is designed (42).  
The accurate staging of the disease followed by a prompt initiation of the appropriate 
therapeutic intervention is crucial in controlling the deleterious symptoms associated with 
breast cancer, prolonging survival, and enhancing patients’ quality of life (43,44). These 
therapeutic modalities include surgical interventions to remove the localized tumor or the 
entire breast, termed as lumpectomy and mastectomy, respectively, radiotherapy, 
chemotherapy, biologic (trastuzumab), and hormonal therapy (42,45–50). Figure 1 
summarizes the different therapeutic modalities involved in the management of breast 
cancer with some examples for each category.  
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Figure 1. Therapeutic modalities involved in the management of breast cancer.  
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Since ER-positive breast cancer comprises the vast majority of breast cancer cases, 
hormonal therapy plays an important role in the management of these patients. Hormonal 
therapy includes 3 different categories; selective estrogen receptor modulators, aromatase 
inhibitors, and gonadotropin analogues (51–53). Among the different hormonal therapies 
currently used in practice, letrozole (LTZ) is considered one of the most promising 
aromatase inhibitors in the realm of breast cancer management. The drug has gained 
attention after demonstrating relatively high effectiveness and safety profile as compared 
with other alternatives, specifically tamoxifen (54,55). The US Food and Drug 
Administration (FDA) has approved the drug as an adjuvant for the treatment of 
hormonally positive local or metastatic breast cancers in postmenopausal women (56). 
The following sections will highlight the clinical benefits of LTZ, its place in therapy, the 
adverse effects associated with it, and the new formulations developed in order to 
overcome its limitations.  
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1.2 Letrozole  
 
In 2004, LTZ was approved by the FDA as extended adjuvant therapy for the treatment 
of ER-positive breast cancer in postmenopausal women after the completion of a 5-year 
tamoxifen therapy (57). A year later, the drug was rapidly approved as an adjuvant 
monotherapy for the same condition without the need for prior administration of 
tamoxifen (58,59). This was due to its proven efficacy elicited from two large, multi-
center trials where patients received LTZ for an average duration of 2-5 years, and 
followed up for about 2.3 and 2.17 years in extended adjuvant and adjuvant monotherapy 
trials, respectively (60–62).         
1.2.1 Mechanism of Action  
 
LTZ is a 3
rd
 generation, irreversible aromatase inhibitor with steroids-free actions. 
Aromatase is a metabolic enzyme that presents in a number of various tissues such as the 
ovaries (prior to menopause), adipose, muscular, hepatic, and breast tissues. It acts as a 
catalyst for estrogen biosynthesis, promoting the conversion of testosterone and 
androstenedione into the freely circulating forms of estrogen; estradiol and estrone, 
respectively (63). In postmenopausal women, aromatase serves as the primary source of 
estrogen supply since the ovaries become inactive (64). Therefore, the inhibitory effects 
of LTZ suppresses the levels of estrogen to more than 99% in just 48-78 hours (65). At 
first, scientist have developed aromatase inhibitors that later were found to have anti-
steroidal actions (1
st
 generation), resulting in numerous adverse effects due to the 
suppression of steroids production. This led to the development of newer agents that are 
 8 
 
of non-steroidal actions with higher potency, efficacy, and selectivity (3
rd
 generation). 
These include LTZ, anastrozole, and exemestane (66). In vitro studies have revealed that 
LTZ has a potency that exceeds that of anastrozole and exemestane 2-5 times, whilst in-
vivo models have shown that the potency of LTZ is even 10-20 times more than its 
competitors (67).       
 
1.2.2 Dosing and Place in Therapy  
 
LTZ is given orally, 2.5 mg daily, marketed as a tablet dosage form (Femara®) (59). Two 
large, multi-center, double-blind, randomized clinical trials have demonstrated its 
superiority over tamoxifen. In the first trial (n=8010), LTZ significantly improved 
disease-free survival (the duration at which the patient did not experience relapse, 
recurrence, metastasis, or death) as compared with tamoxifen (p= 0.002). Although, the 
two drugs did not significantly differ in the overall survival rates, nearly 70% of the 
patients receiving tamoxifen had to switch to LTZ after 2 years of treatment to complete 
another 3 years of LTZ therapy. Upon completion of therapy, those treated with LTZ had 
an overall disease-free survival of 87.4%, whist those who completed their tamoxifen 
therapy had an overall disease-free survival of 84.7% (P= 0.03). Hazards ratio was also 
lower in LTZ arm as compared with tamoxifen arm (95% CI, 0.75–1.02). In addition, 
there was no significant difference between those who received LTZ after initial 
tamoxifen therapy when compared to those who just received LTZ from the beginning in 
terms of disease-free survival (61,62). 
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In the second randomized clinical trial, tamoxifen was given for 5 years followed by LTZ 
for 2 years in one arm. In the other arm, LTZ monotherapy was given for 5 years. Results 
have shown that LTZ monotherapy had significantly higher disease-free survival rates 
over tamoxifen/LTZ therapy (60). Based on these findings, treatment guidelines that have 
long recommended tamoxifen as a first-line option to postmenopausal women with ER-
positive breast cancer, switched to recommend LTZ as a first-line option for these 
patients, instead (42,68).  
 
1.2.3 Chemical Structure and Pharmacokinetic Profile  
 
LTZ is a drug that has a molecular formula of C17H11N5 and a molecular weight of 285.3 
g/mol. It has one major 1,2,4-Triazole group and two nitriles groups which explain the 
basic nature of the drug with a pKa of 1.6 (Figure 2). The drug is crystalline in nature, 
existing in a stable polymorphic form with a melting point of 184-186 °C, and it is 
readily soluble in organic solvents such as dichloromethane, acetone, and acetonitrile 
(57). The water solubility of the drug was reported to be 0.0799 mg/ml. According to the 
Biopharmaceutics Classification System (BSC), LTZ is classified as either class 1 (high 
permeability, high solubility) or class 3 (low permeability, high solubility). Since almost 
20 mg of LTZ (8 times the dose strength; 2.5 mg) can be dissolved in less than 250 ml of 
water (pH 1-7.5), the drug is considered to be highly soluble (69). LTZ is rapidly 
absorbed from the gut as it has a partition coefficient (log P) value of 2.5, giving rise to a 
bioavailability of almost 99.9% (65), which indicates its high permeability. Therefore, 
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LTZ is more likely to be a class 1 drug rather than class 3. In addition, the absorption of 
the drug is not affected by the food which is an advantage over many other drugs. Protein 
binding is not common with LTZ, thus, the drug has a large volume of distribution, 
reaching various tissue types. The metabolism of the drug occurs very slowly via 
CYP3A4 and CYP2A6 hepatic enzymes which convert LTZ into an inactive metabolite 
that is a conjugate of glucuronide (70). Renal excretion represents the major clearance 
pathway where 90% of LTZ was found to be excreted in urine with 6% in an unchanged 
form. Approximately, the reported half-life of the drug is about 2 days, and its 
concentrations reach the steady state in the plasma in an average of 2-6 weeks (71). 
However, these concentrations are found to be 1.5-2 times higher than the estimated 
levels, indicating a non-linear pharmacokinetic release profile (72). Such non-linearity in 
release profile makes the drug exceed its therapeutic window, causing serious adverse 
effects (73). Therefore, it is of high importance to prevent the occurrence of this 
phenomenon through designing new delivery systems with accurately predictable 
pharmacokinetic profiles to keep LTZ within its therapeutic levels without reaching the 
toxic concentrations. 
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1.2.4 Adverse Effects  
 
According to the two clinical trial conducted on LTZ, the drug was found to associated 
with several adverse effects related to cardiovascular, musculoskeletal, respiratory, 
neurologic, and gastrointestinal systems (60–62). Table 1 summarizes the common 
adverse effects experienced with the administration of LTZ among patients.  
 
 
 
Figure 2. Chemical structure of LTZ. 
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1.2.5 Literature Review of Letrozole Formulations  
 
a. Nanospheres Prepared by Nanoprecipitation  
Table 1. Adverse Effects of LTZ 
Adverse effect  Frequency (%)  
Hot flashes 49.7% 
Night sweats 24.2% 
Increased weight  10.7% 
Nausea/ vomiting 7-17% 
Diarrhea/ constipation  8-11.3% 
Fatigue (lethargy, malaise, asthenia) 8.4% 
Dizziness 14.2% 
Myalgia/ arthralgia/ arthritis  22% 
Bone pain/ fractures 5.6% 
Headache 20.1% 
Dyspnea 18% 
Edema 18.5% 
Thromboembolic events 1.1% 
Pulmonary embolism 2% 
Myocardial infarction  0.5% 
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Nanoprecipitation is a simple, easy, and highly reproducible technique that allows rapid 
formation of nanoparticles. Ever since its development by Fessi et al. in the late nineties 
(74), the technique has gained considerable attention in preparing polymeric drug 
delivery carriers. In this technique, a polymer is basically dissolved in a volatile solvent 
that is miscible with water to form a polymeric solution. This formed solution is then 
poured slowly into surfactant-containing aqueous medium, causing the solvent to diffuse 
quickly to the aqueous phase, resulting in the precipitation of the polymer as 
nanoparticles. Therefore, the technique was termed “solvent displacement”, and both 
expressions are used interchangeably nowadays (75).  
Recently, Mondal and colleagues have utilized this technique in their attempt to prepare a 
new formulation of LTZ that would offer sustained-release actions of the drug (76). 
Formulations of varying polymer-to-drug ratios (5:1, 10:1, and 20:1) were prepared using 
acetone as a solvent and poly (D, L-lactide-co-glycolide) (PLGA) as a polymeric carrier. 
The authors were successful in generating spherical LTZ-PLGA nanoparticles with 
smooth surfaces, which held the potential of offering enhanced controlled-release actions. 
In addition, the produced particles were ranging from 140 nm to 167 nm. It was reported 
that particles with aerodynamic diameters less than 300 nm are easily transported across 
cell membranes (77). Therefore, the formulated particles in this study were expected to 
possess reasonable penetration through the cancerous tissues. However, the drug 
entrapment efficiency in these formulations was very low with 27% being the highest 
percentage obtained. This represents a critical limitation in their study which could be 
attributed to several factors such as the use of a high mixing speed (78), rapid addition of 
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the polymer solution to the aqueous phase (79), high concentration of the surfactant (80), 
and the use of a strong solvent such as acetone which resisted the precipitation of PLGA 
(81). The first three factors could be modified by simply decreasing the mixing speed and 
the concentration of the used surfactant with drop-wise addition of the polymer solution 
to the aqueous medium. Nevertheless, the last factor is not as simple. Although it is true 
that the use of less soluble solvents would facilitate polymer precipitation, and as such 
would improve drug entrapment efficiency, reduction in polymer solubility would 
diminish its elasticity, and hence, would result in less efficient drug release from the 
polymer (82). Thus, to overcome this issue, it is better to seek another technique that is 
not affected by the type of solvent used such as dispersion-solvent evaporation which 
conquers the limitations of the precipitation technique (83).  
b. Nanospheres Prepared by Emulsification  
This technique is very similar to the nanoprecipitation technique with the only exception 
being the use of two immiscible solvents. This implies that both the polymer and the drug 
are dissolved in a solvent that is not miscible with the external phase to which they are 
dispersed in (84). Different types of emulsions have been produced through altering the 
dispersed phase and the dispersion medium. These include oil in water (o/w), water in oil 
(w/o), water in oil in water (w/o/w), oil in water in oil (o/w/o), and many other complex 
systems (85). In usual emulsification procedures, micro-sized droplets are formed and 
dispersed in the continuous phase due to differences in surface tension between the two 
phases (86). The reduction in droplet size is enabled through diverse mechanisms such as 
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homogenization, ultra-sonication, and microfluidic filtration. Despite the variations in the 
three mechanisms, they all carry the same concept of applying external forces on the 
dispersed droplets, producing a shearing stress that breaks them down into smaller sizes 
(87,88). 
In 2009, the group of Mandal et al. used the dispersion-solvent evaporation technique in 
preparing LTZ-PLGA nanoparticles. In general, LTZ and PLGA were dissolved in 
dichloromethane, and this solution was then added slowly to an aqueous phase to form a 
dispersion. The formed dispersion was subjected to ultra-sonication for particle size 
reduction, followed by mechanical stirring to evaporate the solvent, and finally 
lyophilization was carried out to eliminate the water from the formulation in order to 
obtain dried LTZ-PLGA nanoparticles (89). Generated particles from this technique were 
ranging from 64 nm to 255 nm in size with a poly-dispersity index range of 0.27 to 0.66. 
Although the particle size was within an acceptable range that would ensure tissue 
penetration, the wide size distribution as indicated by the poly-dispersity index may 
impact the homogeneity of particles uptake by the cells (90). In contrast to the previous 
trial that used solvent precipitation technique, the entrapment efficiency obtained with 
this technique was very high, ranging from 68% to 82%. On the other hand, in vitro 
release studies revealed that LTZ release from PLGA in these formulations followed 
zero-order kinetics which entails that concentration-independent drug release actions 
were achieved (91). However, there was an initial burst release of LTZ encountered. This 
could be related to the type of PLGA used which consisted of 75% lactic acid: 25% 
glycolic acid. The high content of lactic acid triggered the autocatalytic degradation of 
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the polymer chains which accelerated the release of the drug. Therefore, whenever PLGA 
is used, lower contents of lactic acid (≤ 50%) should be selected in order to avoid the 
burst effect (92).   
c. Solid Lipid Nanoparticles  
Solid lipid nanocarriers are recently emerging drug delivery systems evolved as 
alternatives to polymeric carrier systems. They consist of a single layer of 
physiologically-tolerated lipids that encloses inside its core the hydrophobic solid drug 
particles (93). The inclusion of a lipid bilayer would create an aqueous core for the 
encapsulation of water-soluble drugs, and such a system is called a liposome (94,95). 
Basically, the lipid shell is formed when the lipid particles which are amphiphilic in 
nature (composed of hydrophilic heads and hydrophobic tails) are placed in an aqueous 
medium. The hydrophilic heads immerse themselves inside the aqueous phase, exposing 
their tails to the surface. Upon increasing the concentration of the lipid particles above 
their critical micelle concentration, they align themselves in a circle with polar heads 
exposed to the water phase and non-polar tails hidden towards the core. This 
phenomenon occurs since this alignment establishes a more favorable thermodynamic 
state for the lipid particles, providing them with lowest energy levels, and yet, highest 
physiochemical stability levels (96).   
These lipid-based carriers hold the advantage of being less toxic to the biological systems 
as compared with polymeric carriers owing to their tolerable lipid composition. In 
addition, reports have shown that these systems have higher bioavailability than 
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polymeric systems which is again due to their lipid composition which is close to that of 
the physiologic membranes, making their cellular uptake easier and more favorable than 
the polymeric carriers (97).  
Recently, Nerella et al. presented a new formulation of LTZ-solid lipid nanoparticles 
using trimyristin as a solid lipid core. Briefly, LTZ, trimyristin, and surface active agents 
were mixed with methanol and chloroform (50%:50%). The solvent was evaporated 
using rotary evaporator by heating at 62 °C. An aqueous phase was heated also at 62 °C, 
and then added to the drug-containing mixture. Particle size reduction was facilitated 
through homogenization followed by ultra-sonication (98). Of the eight different 
formulations prepared, one formulation carried promising results. In this formulation, the 
particles were 29 nm in size with very narrow size distribution as indicated by a poly-
dispersity index of 0.162, and a very high entrapment efficiency of 85.6%. In vitro 
release studies showed that the drug followed first order kinetics over a 24-hours period. 
The formulation was stable for one month only where significant changes in the 
formulation characteristics were observed after one month. Such limitation is related to 
the lipid composition of the formulation which is thought to possess various degrees of 
polymorphism, resulting in drug leakage (97). Since this formulation seems very 
promising, optimizing its stability is worthwhile. Decreasing the water content and 
increasing the concentration of surfactants could be valid options to enhance the stability 
of this formulation. In-vivo studies are also needed to investigate the efficacy, safety, and 
pharmacokinetic profile of this formulation.  
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d. Niosomes  
Niosomes are newly developed drug delivery systems that are very similar to liposomes 
in structure. The only difference between the two systems is that niosomes are composed 
of a single bilayer of non-ionic surfactants (which consist of one polar head and one non-
polar tail) with cholesterol (99). On the other hand, liposomes are composed of a single 
bilayer of phospholipids (which consist of one polar head and two non-polar tails) with or 
without cholesterol. Similar to liposomes, niosomes are thought to have higher 
biocompatibility and bioavailability when compared to other polymeric drug delivery 
systems. Therefore, much attention is being paid on the utilization of these carriers for 
drug delivery purposes (100).  
Norouzian and Azizi have recently reported a new formulation of LTZ incorporated into 
a PEGylated niosomal system. In summary, LTZ, polyethylene glycol (PEG), cholesterol, 
and surfactants (tween and span 60) were dissolved in alcohol under mechanical stirring 
for half an hour. Alcohol was evaporated using rotary evaporator. After adding a 
phosphate buffer saline at physiologic pH, the mixture was subjected to ultra-sonication 
at 40 °C to produce nano-sized niosomes (101). The obtained formulation achieved a 
relatively high entrapment efficiency of LTZ (66.6%). In addition, in vitro release of LTZ 
was seen to follow first-order kinetics, reflecting the ability of the system to sustain the 
release of LTZ over 48 hours (91). More importantly, this formulation demonstrated less 
toxic effects than pure LTZ according to the in vitro studies. Although the results of this 
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study showed promising findings, it failed to report several important characteristics of 
the prepared formulation such as particle size distribution, thermal analyses, and stability 
studies which are needed to have a clear picture about the proposed claims. Moreover, the 
reproducibility of this formulation is somewhat doubtable since the authors just reported 
the results of one experiment only. Therefore, it is advisable to run more experiments in 
order to increase the reliability of their results. This, however, should not prevent other 
researchers from considering the use of the niosomal carriers as a viable option for 
effective drug delivery system.         
 
1.3 Monodisperse Microparticles as Drug Delivery Systems 
 
The term ‘monodisperse’ refers to particles with a narrow size distribution. This entails 
that the particles have nearly similar shape and size, appearing almost identical under 
microscopic analysis (102–107). Such highly uniform particles are highly favored for 
drug delivery purposes over polydisperse particles which have a wider particle size 
distribution and heterogeneous nature (106,108,109). This is because the behavior of 
monodisperse particles in both in vitro and in vivo systems can be predicted with high 
accuracy. This means that when monodisperse particles are used as drug carriers, they 
can deliver equal amounts of drug per particle, resulting in optimized release profile 
kinetics for the delivered drug. This is mainly due to the fact that drug release from 
highly uniform particles can be accurately determined from the previously calculated 
surface area with respect to the volume and the equivalent distances between the diffused 
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drug particles and/or rate of degradation of the polymeric carrier (110–122). Therefore, 
the progression towards in-vivo studies would maintain its repeatability as that of in vitro 
testing. This is of high importance since such constant drug delivery to target sites inside 
the body would offer controlled drug release over extended periods of time, preventing 
the fluctuations of the drug’s levels, which would eventually maintain the concentrations 
of the drug within its therapeutic range. The ultimate goal of this is to minimize the 
undesirable adverse effects of the drug and increase patient compliance (122–127). 
In any drug delivery system, monodisperse particles present an outstanding performance 
over polydisperse counterparts. In pulmonary drug delivery systems, for instance, the 
administration of monodisperse particles would ensure their delivery to the specific site 
as minor differences in size distribution would result in particles being deposited in 
unwanted regions of the pulmonary systems (77,128). Likewise, systemic routes of 
administration such as intravenous (IV) and intramuscular (IM) routes of anticancer drugs 
in a monodisperse fashion would facilitate the targeted embolization of tumor vessels 
(129).  
Although monodispersity has been discussed extensively in literature, universal 
standardization for the term ‘monodisperse’ is lacking. In addition, there is a scarcity in 
the well-established measures for assessing how truly the produced particles meet the 
criteria of monodispersity (130). Thus, it is essential to define a set of criterion for 
monodispersity in order to be able to evaluate the success of a method in producing actual 
monodisperse microparticles. Upon extensive literature review, particles are thought to be 
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monodispersed if their median size distribution expressed in ‘span’ values is <0.3, or if 
the coefficient variation of their size distribution is <3.001%. Now, the span refers to a 
well-known parameter used to measure the width of the size distribution. It is calculated 
as: Span= (D90 - D10)/ D50.  
Where D90, D10, and D50 represent the median diameter by which 90%, 10%, and 50% 
of the size distribution has a smaller particle size than the given value of the equation 
(111,116,118,121,122,131,132).     
   
1.4 Vibrating Orifice Aerosol Generator (VOAG) 
 
Vibrating Orifice Aerosol Generator (VOAG) is an instrument that was developed by 
Berglund-Liu in 1973 (133). The instrument was designed originally to produce a 
constant jet of monodisperse liquid droplets that would dry off upon passing a drying 
column, leaving the solutes that were dissolved in that liquid in the form of monodisperse 
microparticles (Figure 3) (134). The VOAG could also be operated in an inverted 
position where the liquid jet stream would fall down instead of travelling up the column. 
In order to use the VOAG in generating monodisperse microparticles, an organic solution 
of LTZ along with a polymeric carrier; either Polycaprolactone (PCL), or Poly(D,L-
Lactide) (PDLLA) would be injected into the VOAG, and upon passing an extremely 
narrow orifice, vibrating at frequency of 100-1000 kHz, a monodisperse cylindrical liquid 
jet would be formed. Afterwards, this jet would eventually get broken down into 
microdroplets as a result of the orifice vibration. With the flow of a dry air, the 
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microdroplets would be dried, forming the intended monodispersed microparticles which 
would be collected in the cylindrical chamber.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation of the VOAG (135).  
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1.5 Study Hypothesis 
 
This study hypothesized that if LTZ was incorporated into monodisperse polymeric 
microparticles either using PCL or PDLLA, the new complex would possess improved 
release kinetics profile,  and hence, the safety of LTZ would be potentially improved. 
 
1.6 Study Objectives 
 
1. To prepare monodispersed LTZ-loaded polymeric-based microparticles via the VOAG 
instrument using either PCL or PDLLA as drug carriers.  
2. To screen for and identify the significant factors affecting particle size distribution in 
order to optimize the prepared formulations. 
3. To characterize the optimized formulations in terms of yield, morphology, particle 
size, zeta potential, thermal properties, physical state, drug loading, and entrapment 
efficiency.  
4. To investigate the drug release profile through in vitro dissolution study. 
5. To investigate the cellular cytotoxicity of the optimized formulations against 
conventional LTZ on MCF-7cells.  
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Chapter 2: Materials and Methods   
2.1 Materials and Equipment 
 
Table 2 summarizes the materials used in conducting the experiments. All chemicals 
were used as supplied without any further purification or chemical modification.  
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Table 2. Summary of the Chemicals Used in the Study  
Substance   Suppling company  
Letrozole  Jiangsu Ainty Handsome  CO., 
LTD (China) 
Poly(D,L-Lactic acid), MW 15000, IV 0.2 dl/g Polysciences, Inc. (PA, USA) 
Polycaprolactone, MW 50000, powder Polysciences, Inc. (PA, USA) 
Dichloromethane (HPLC gradient grade, 99.8%) Sigma-Aldrich Co. LLC (Germany) 
Polyvinyl alcohol (88% hydrolyzed) Sigma-Aldrich Co. LLC (Germany) 
Polystyrene monodisperse microparticles, 20 µm Sigma-Aldrich Co. LLC (Germany) 
Transcutol® HP Gattefossé (Lyon, France) 
Acetonitrile gradient grade Merk Co. (Germany) 
Potassium chloride (purity: 99.9%)  BDH LLC. (UK) 
Dialysis tubing cellulose membranes (MW cut-off = 14,000) Sigma-Aldrich Co. LLC (Germany) 
MCF7 (ATCC® HTB-22™) cell line ATCC®, VA, USA 
Primary Mammary Epithelial Cells; Normal ATCC®, VA, USA  
Eagle's Minimum Essential Medium (EMEM)  ATCC®, VA, USA  
Mammary Epithelial Cell Basal Medium  ATCC®, VA, USA  
Mammary Epithelial Cell Growth Kit  ATCC®, VA, USA  
Penicillin-Streptomycin-Amphotericin B Solution  ATCC®, VA, USA  
Trypsin-EDTA Solution, 1X  ATCC®, VA, USA  
Trypsin Neutralizing Solution  ATCC®, VA, USA  
Dulbecco's Phosphate Buffered Saline (D-PBS), 1X  ATCC®, VA, USA  
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2.2 Optimization of the Monodisperse Microparticles Production Process 
 
The use of the VOAG in producing monodisperse microparticles was accompanied with 
several challenges that restricted the operational process and resulted in a very low yield. 
These included instability in liquid pressure that builds up upon passing through the tubes 
of the instrument, persistent clogging of the orifice which prevented the consistent liquid 
feed, inefficient drying system, and difficulty in collecting the particles. Therefore, a 
number of modifications were implemented in order to optimize the production process, 
facilitate handling of the instrument, maximize the percentage yield, and minimize 
material loss. To stabilize liquid pressure, the Teflon O-ring (0.075 mm in thickness) that 
holds the orifice disc was replaced with a rubber O-ring (2 mm in thickness). To 
overcome the issue of persistent clogging of the orifice, the orifice disc that had a hole 
diameter of 20 µm was replaced with a specially manufactured orifice disc purchased 
from Lenox Laser, Inc. (MD, USA) with the following parameters:  
Disc diameter: 9.5 mm ± 0.26% mm  
Hole diameter: 300 µm ± 5% µm 
Thickness: 0.05 mm ± 5% mm    
Centering: ± 0.25 mm 
Finally, in an effort to overcome the inefficient drying system that led to the difficulty in 
collecting the particles, the drying column was removed and the liquid chamber base was 
inverted and mounted on a beaker where the dispersion cap was totally immersed in the 
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collecting medium inside the beaker. The collecting medium consisted of 0.04-1% 
Polyvinyl Alcohol (PVA) aqueous solution.       
 
2.3 Preparation of Polymeric Monodisperse Microparticles Loaded with 
Letrozole  
 
An amount of 1 g PCL or PDLLA was mixed with 5-30% w/w LTZ in 1-2 % w/v ml 
dichloromethane. The resulting organic solution was filled into the syringe connected to 
the pump of the VOAG to flow at a rate of 0.17-1.7 ml/min. Upon passing the 300 µm 
orifice vibrating at a frequency of 100-1000 KHz, a constant stream of monodispersed 
microdroplets was generated. These droplets were collected in a 0.04-1% Polyvinyl 
Alcohol (PVA) aqueous medium which served as a stabilizer to prevent particles 
aggregation (75). Before choosing PVA to prevent particles aggregation, different 
surfactants were tried such as Tween 20, Tween 80, Span 20, Span 80, and sodium lauryl 
sulfate. However, all of these surfactants did not maintain an adequate dispersion of the 
particles, therefore, PVA was selected as it appeared to efficiently prevent particles 
aggregation. The ratio of the organic medium: aqueous medium was 1:4-1:8 v/v. The 
formed dispersion was stirred at 250-500 rpm, ambient temperature for 24 hours to 
ensure complete solvent evaporation. Solidified microparticles were collected through 
filtration, washed several times with distilled water to remove residual PVA, and then 
centrifuged at 5°C, 8500 rpm for 10 minutes, and finally dried under vacuum at -19 Kpa 
at 35°C over 48 hours.  
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Production parameters such as drug loading, organic phase concentration, liquid flow 
rate, frequency, PVA concentration, organic: aqueous phase ratio, and stirring rate were 
screened to explore their effects on particle size and particle size distribution using a 12-
run Plackett-Burman design (136). The optimal parameters as revealed by the Plackett-
Burman design were used in further experiments in order to produce the most 
homogenous monodisperse microparticles possible. These optimized particles obtained 
were characterized for percentage yield, microscopic morphology, particle size, zeta 
potential, drug loading, drug entrapment efficiency, thermal properties, physical 
characteristics, drug release kinetics, and in vitro cytotoxicity. 
 
2.1 Experimental Design for Optimizing the Production Parameters  
 
Multiple factors involved in the production process of monodisperse particles were 
thought to have an effect on particle size distribution including drug loading, organic 
phase concentration, organic: aqueous phase ratio, PVA concentration, frequency of the 
vibrating orifice, liquid flow rate, and stirring rate (137). Therefore, it was essential to 
study the effects of these factors on particle size distribution in order to determine the 
optimal values of each one that would yield optimal monodisperse particles. Thus, a 
screening of the 7 factors that were thought to have an impact on particle size distribution 
was constructed based on Plackett-Burman design which is a powerful tool that allows 
the accurate identification of major factors influencing an outcome with a minimal 
number of experiments. This is because Plackett-Burman design is a fractional factorial 
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design that combines the advantage of accuracy of full factorial designs and the few 
experimental runs of fractional factorial designs. Therefore, the use of Plackett-Burman 
design is very reasonable in determining the factors that significantly affect the particle 
size distribution and specify the optimal values that would result in the desired outcomes. 
Using Minitab
® 
17 Statistical Software (Coventry, UK), a 12-run, 2-level Plackett-
Burman design was created with each run containing a combination of the different levels 
of the following factors: drug loading (X1), organic phase concentration (X2), organic: 
aqueous phase ratio (X3), PVA concentration (X4), frequency of the vibrating orifice 
(X5), liquid flow rate (X6), and stirring rate (X7). The highest and lowest levels for each 
factor were selected based on the reported results of previous studies in literature 
(136,138,139). Table 3 illustrates the 12-run Plackett-Burman design with all different 
combinations. Each run was done in triplicate for each polymeric carrier; PCL and 
PDLLA. Particles generated from each run were analyzed for their  particle size 
distribution where the average span values were calculated and reported. The main effects 
of each of the 7 factors on the average span values were examined using Minitab
® 
17 
Statistical Software.         
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Formulation Drug 
loading 
(%w/w) 
Organic phase 
concentration 
(%w/v) 
Organic: 
aqueous phase 
ratio 
PVA 
concentration 
(%w/v) 
Frequency 
(KHz) 
Liquid 
flow rate 
(ml/sec) 
Stirring 
rate 
(rpm) 
 F1 5 1 1: 8 0.1 1000 0.17 500 
F2 30 2 1: 4 0.1 100 0.17 250 
F3 30 1 1: 8 0.04 100 0.17 500 
F4 5 2 1: 8 0.04 1000 0.17 250 
F5 30 2 1: 4 0.1 1000 0.17 500 
F6 5 2 1: 8 0.1 100 1.7 500 
F7 30 2 1: 8 0.04 1000 1.7 250 
F8 5 2 1: 4 0.04 100 1.7 500 
F9 5 1 1: 4 0.04 100 0.17 250 
F10 5 1 1: 4 0.1 1000 1.7 250 
F11 30 1 1: 4 0.04 1000 1.7 500 
F12 30 1 1: 8 0.1 100 1.7 250 
 
Table 3. Plackett-Burman Design for Optimizing PCL- and PDLLA-based Formulations 
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2.2 Ultra-Performance Liquid Chromatography (UPLC) Validation  
 
2.2.1 UPLC Specifications 
 
International Council for Harmonization (ICH) guidelines were followed in the 
validation process (140). Table 4 summarizes the specific instrument, 
accessories, and parameters used during the validation process.  
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Table 4. Summary of the UPLC Specifications  
Component    Description  
Instrument  ACQUITY UPLC
®
 H-Class System 
Column  ACQUITY UPLC
®
 BEH C-18 (2.1 x 50 mm, 1.7 µm particle 
size) 
Detector  ACQUITY UPLC
®
 Tunable UV Detector, set at λ= 240 nm 
Mobile phase Acetonitrile: Water (35:65, v/v) under isocratic conditions   
Diluent and solvent  Acetonitrile 
Flow rate 0.3 ml/min 
Injection volume 1 µl 
Column temperature 25 °C 
Sample temperature        20 °C 
Retention time Approximately 1.8 min 
Filter  Polytetrafluoroethylene (PTFE) 0.2 µm 
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Standard and sample solutions were both prepared by dissolving 25 mg LTZ in 50 ml 
acetonitrile in a volumetric flask through vigorous shaking followed by 5 minutes of 
sonication, and then diluting 5.0 ml of this solution using the mobile phase in a 50.0 ml 
volumetric flask to make up a final concentration of 50.0 µg/ml. Before injection, the 
solutions were filtered using 0.2 µm PTFE filters. For accurate measurements, fresh 
standard and sample solutions were prepared on the day of injection.    
 
2.2.2 System Suitability 
 
It was essential to confirm that the UPLC system would be appropriate for the detection 
of LTZ from its formulations. In order to do so, peak area, tailing factor, retention time, 
and theoretical plates were quantified.  
 
2.2.3 Forced Degradation Studies 
 
These studies were very important as they provide an evidence of how stable and specific 
the method is in analyzing LTZ content from the prepared formulations. Stock solutions 
were prepared by dissolving 25.0 mg LTZ in 50.0 ml acetonitrile (500 µg/ml) in a 
volumetric flask which was placed in a cold water bath for 30 minutes of sonication to 
ensure complete dissolution of LTZ. These solutions were then filtered using double 0.2 
µm PTFE filters, subjected to freezing at -4 °C for 3 hours, removed from the freezer and 
kept at room temperature for 15 minutes, and finally filtered again using 0.2 µm PTFE 
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filters. This step was done to ensure that all impurities got precipitated in order to 
minimize the blockage of the UPLC column as it was found to be effective in our 
preliminary trials while working with the UPLC system. However, this was not validated 
in this study as the time did not permit for that. In addition, it was very important to 
conduct the forced degradation studies in the presence of the two polymers; PCL and 
PDLLA to provide a comprehensive stability profile of the produced formulations. 
However, due to time limitation, this was done only on LTZ alone, and as such this was a 
limitation in this study. Therefore, these experiments should be incorporated in our future 
studies.  
2.2.3.1 Acidic Stability 
 
A 5.0 ml of the stock solution (500 µg/ml) was placed in a round bottom flask to which 
5.0 ml of 0.1 N HCL was added. The mixture was refluxed for 2 hours at 80 °C. After 
that, the solution was allowed to cool down, and then transferred to a 50.0 ml volumetric 
flask to be neutralized by adding 5.0 ml 0.1 N NaOH and toped up with acetonitrile to 
yield a final concentration of 50 µg/ml. Another 5.0 ml of the stock solution (500 µg/ml) 
was also diluted with acetonitrile in a 50.0 ml volumetric flask to yield a final 
concentration of 50 µg/ml. This solution served as a standard to measure the difference in 
LTZ concentration after being exposed to a stress acidic environment. The percentage of 
LTZ degradation was calculated using the following formula: 
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% LTZ degradation =
LTZ concentration after acidic stress
LTZ concentration without any stressful condition
 x 100 
 
 
2.2.3.2 Basic Stability 
 
A 5.0 ml of the stock solution (500 µg/ml) was placed in a round bottom flask to which 
5.0 ml of 0.1 N NaOH was added. The mixture was refluxed for 2 hours at 80 °C. After 
that, the solution was allowed to cool down, and then transferred to a 50.0 ml volumetric 
flask to be neutralized by adding 5.0 ml 0.1 N HCL and toped up with acetonitrile to 
yield a final concentration of 50 µg/ml. Another 5.0 ml of the stock solution (500 µg/ml) 
was also diluted with acetonitrile in a 50.0 ml volumetric flask to yield a final 
concentration of 50 µg/ml. This solution served as a standard to measure the difference in 
LTZ concentration after being exposed to a stress basic environment. The percentage of 
LTZ degradation was calculated using the following formula: 
  
% LTZ degradation =
LTZ concentration after basic stress
LTZ concentration without any stressful condition
 x 100 
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2.2.3.3 Oxidative Stability  
 
A 5.0 ml of the stock solution (500 µg/ml) was placed in a round bottom flask to which 
5.0 ml of 3% H2O2 was added. The mixture was refluxed for 2 hours at 80 °C. After that, 
the solution was allowed to cool down, and then transferred to a 50.0 ml volumetric flask 
and toped up with acetonitrile to yield a final concentration of 50 µg/ml. Another 5.0 ml 
of the stock solution (500 µg/ml) was also diluted with acetonitrile in a 50.0 ml 
volumetric flask to yield a final concentration of 50 µg/ml. This solution served as a 
standard to measure the difference in LTZ concentration after being exposed to an 
oxidative stress. The percentage of LTZ degradation was calculated using the following 
formula: 
  
% LTZ degradation =
LTZ concentration after oxidative stress
LTZ concentration without any stressful condition
 x 100 
 
 
2.2.3.4 Thermal Stability  
  
A 5.0 ml of the stock solution (500 µg/ml) was diluted with acetonitrile in a 50.0 ml 
volumetric flask to yield a final concentration of 50 µg/ml. This solution was heated at 80 
°C for 4 hours, then cooled down and injected in the UPLC to measure LTZ 
concentration. LTZ concentration detected from this solution was compared with a 
diluted stock solution (50 µg/ml) to calculate the percentage of LTZ degradation after 
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being exposed to excessive heating. The percentage of LTZ degradation was calculated 
using the following formula: 
% LTZ degradation =
LTZ concentration after heating 
LTZ concentration without any stressful condition
 x 100 
 
 
2.2.3.5 UV-radiation Stability 
 
A 5.0 ml of the stock solution (500 µg/ml) was diluted with acetonitrile in a 50.0 ml 
volumetric flask to yield a final concentration of 50 µg/ml. This solution was exposed to 
UV light (λ= 365 nm) at room temperature for 4 hours, then injected in the UPLC to 
measure LTZ concentration. LTZ concentration detected from this solution was 
compared with a diluted stock solution (50 µg/ml) to calculate the percentage of LTZ 
degradation after being exposed to UV light. The percentage of LTZ degradation was 
calculated using the following formula: 
% LTZ degradation =
LTZ concentration after UV light exposure 
LTZ concentration without any stressful condition
 x 100 
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2.2.3.6 Photo-stability 
 
A 5 ml of the stock solution (500 µg/ml) was diluted with acetonitrile in a 50 ml 
volumetric flask to yield a final concentration of 50 µg/ml. This solution was exposed to 
visible light for at room temperature 24 hours, then injected in the UPLC to measure LTZ 
concentration. LTZ concentration detected from this solution was compared with a 
diluted stock solution (50 µg/ml) to calculate the percentage of LTZ degradation after 
being exposed to visible light. The percentage of LTZ degradation was calculated using 
the following formula: 
% LTZ degradation =
LTZ concentration after visible light exposure 
LTZ concentration without any stressful condition
 x 100 
 
2.2.4 Selectivity and Specificity  
 
The selectivity and specificity of the analytical procedure was assessed by comparing the 
purity chromatograms of LTZ peaks obtained from the acidic, basic, oxidative, UV-
radiation, and photo-stability studies. The chromatograms were compared with that of a 
pure LTZ standard solution (50 µg/ml), freshly prepared without being exposed to any 
stressful condition. The ability of the analytical method to separate LTZ peak from other 
peaks pertaining to the degradation products was an indication of its selectivity and 
specificity.   
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2.2.5 Precision 
 
An accurately weighed amount of 25 mg LTZ was dissolved in 50 ml of acetonitrile in a 
volumetric flask. The solution was sonicated for 30 minutes in a cold water bath to ensure 
complete dissolution of LTZ. Then it was filtered using 0.2 µm PTFE filters and put in 
the freezer at approximately -8 °C for 3 hours. Afterwards, the solution was allowed to 
warm up by leaving it at room temperature for 15 minutes. This was followed by another 
round of filtration using 0.2 µm PTFE filters, and finally the solution was diluted with 
acetonitrile to make up a final concentration of 50 µg/ml. The solution was then injected 
in the UPLC system to measure LTZ concentration to explore intra-day precision. For 
inter-day precision, similar procedure has been followed across two days. The test was 
made in 6 replicates with each being injected twice. The mean and RSD were reported.   
 
2.2.6 Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
 
Limit of Detection (LOD) represents the least concentration of the substance in a sample 
(i.e., LTZ in this case) that can be detected by the analytical procedure but not necessarily 
quantified. Limit of Quantitation (LOQ), on the other hand, represents the least 
concentration of the substance in a sample that can be accurately and precisely calculated 
and quantified (140). LOD and LOQ were determined from the calibration curve where 
different known concentrations of LTZ (n=11) were injected in UPLC and plotted against 
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their corresponding areas as measured by the UPLC system. LOD and LOQ were 
calculated using the following equations: 
LOD = (3.3 * SD)/ Slope  
LOQ= (10 * SD)/ Slope  
Where the slope was obtained from the linear equation of the calibration curve, and the 
SD was computed for the residuals of the regression line.  
 
2.2.7 Linearity 
 
A stock solution was prepared by dissolving 25 mg LTZ in 50 ml acetonitrile in a 
volumetric flask (500 µg/ml), followed by sonication for 5 minutes. A total of 11 
solutions with different concentrations were made from that stock solution (0.5, 1, 2.5, 5, 
10, 25, 50, 100, 150, 200, 250 µg/ml) and injected in UPLC for analysis. The 
concentrations were plotted against their corresponding areas obtained from the UPLC 
system. A fitted regression line having least residual sum of squares was drawn and its 
equation displaying the slope and y-intercept was reported.  
 
2.2.8 Accuracy 
 
Accuracy was assessed by measuring the percentage recovery of 3 different LTZ 
concentrations (40, 50, 60 µg/ml) prepared from the stock solution (500 µg/ml) as 
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previously described. The solutions were injected in UPLC and their corresponding 
concentrations were compared with a standard solution having a LTZ concentration of 50 
µg/ml. Percentage recovery was calculated by the following equation: 
% Recovery =
LTZ concentration obtained from the sample 
LTZ concentration obtained from the standard
 x 100 
The experiment was done in triplicate and the mean and RSD values were reported.  
  
2.2.9 Effect of Filtration  
 
Filtration is an essential part of the analytical procedure. Samples must be filtered prior to 
their injection into the UPLC system to prevent the entry of large particles that may clog 
the column and damage it. At the same time, it is necessary to ensure that the filter does 
not interfere with the active substance to be analyzed in order to get accurate results. Two 
types of filters were assessed for their efficiency to be used for filtering samples 
containing LTZ; 0.2 µm PTFE and 0.2 µm Nylon filters. To compare between these 
filters, 25 mg LTZ was dissolved in 50 ml of acetonitrile in a volumetric flask (500 
µg/ml). The solution was sonicated for 30 minutes in a cold water bath to ensure 
complete dissolution of LTZ. Then it was filtered using either PTFE or Nylon filters and 
put in the freezer at around -8 °C for 3 hours. Subsequently, the solution was allowed to 
warm up by leaving it at room temperature for 15 minutes. This was followed by another 
round of filtration using either PTFE or Nylon filters, and finally the solution was diluted 
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with acetonitrile to make up a final concentration of 50 µg/ml. The solution was then 
injected in the UPLC system to measure LTZ concentration and this was compared with a 
standard LTZ solution (50 µg/ml) prepared similarly, but without filtration in order to 
calculate the percentage recovery. The experiment was done in 7 replicates and the mean 
and RSD were reported.  
 
2.2.10 Solution Stability 
 
Stability of LTZ solutions was evaluated at two storing conditions; at room temperature 
and in refrigerator (5 °C). Standard and sample solutions having LTZ concentrations of 
50 µg/ml were prepared as previously described and stored in tightly closed unwrapped 
containers at room temperature and in refrigerator (5 °C) for 48 hours. The solutions were 
assayed using the UPLC system at 24 and 48 hours and percentage recovery was 
calculated by dividing LTZ concentrations obtained from the samples over LTZ 
concentrations obtained from the standards, multiplied by 100. The experiment was done 
in 6 replicates and the mean and RSD were reported.  
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2.3 Characterization of the Optimized Polymeric Monodisperse Microparticles 
Loaded with Letrozole 
 
2.3.1 % Yield 
 
Produced monodisperse microparticles were collected from the filter papers using a clean 
spatula, then weighed to observe how much was obtained from the initial amount used in 
preparing the formulations. The yield was calculated using the following formula: 
% Yield= (Actual weight of the obtained microparticles)/ (Theoretical weight of the 
microparticles)  x 100 
 
2.3.2 Morphological Analysis  
 
Approximately 5-10 mg of the dried monodisperse microparticles were spread on a 
double-sided tape fixed on an aluminum holder and then sprayed with a gold layer of 
around 20 nm in thickness. Imaging was carried out at 15.0 kV using Nova NanoSEM 
450™ scanning electron microscope (FEI, California, USA).   
 
2.3.3 Particle Size Analysis 
  
Samples were appropriately diluted using distilled water and analyzed at a temperature of 
25°C by the dynamic light scattering technology offered by the Mastersizer 2000 
(Malvern Instruments Ltd., UK). Particle size and size distribution were determined by 
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measuring the mean hydrodynamic diameter and the span, respectively. The mean value 
of 3 replicates was calculated for each formulation.  
 
2.3.4 Zeta Potential Analysis 
 
Zeta potential was determined using laser Doppler micro-electrophoresis offered by 
Zetasizer Nano ZS (Malvern Instruments, Ltd, UK). Distilled water or 0.1 M KCL 
solution were used to dilute the samples (2-3 mg) which were analyzed through the 
instrument’s software. Each value reported represented the mean of 3 replicates for each 
formulation.  
 
2.3.5 Thermal Properties 
 
Thermal characteristics of the obtained formulations were attained via Differential 
Scanning Calorimetry using the DSC 8000 instrument (Perkin Elmer Co., USA) equipped 
with the intra-cooling system (Intracooler II, Perkin Elmer Co., USA). Approximately 2-4 
mg of each formulation was placed into an aluminum pan tightly sealed with an 
aluminum cover and scanned over a temperature range of 0 - 200°C or -70 - 200°C for 
PDLLA- and PCL-based formulations, respectively, with a rate of 10°C/min. Nitrogen 
gas flow was set at 40 ml/min to eliminate humidity that might affect the scanning. Pure 
LTZ, PCL, PDLLA, physical mixtures of LTZ and PCL/PDLLA, LTZ-PCL formulations, 
and LTZ-PDLLA formulations were analyzed through DSC.    
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2.3.6 Structural Characterization 
 
Physical structure studies were performed using X-ray diffractometer (D8 Advance, 
Bruker Co., Germany) by employing CuKα radiation source. Pure LTZ, PCL, PDLLA, 
physical mixtures of LTZ and PCL/PDLLA, LTZ-PCL formulations, and LTZ-PDLLA 
formulations were analyzed using A1° divergence slit between the 2θ range 5-60°C with 
a step size of 0.1°C and step time of 1 sec. DIFFRAC.EVA software was used to obtain 
the resulted XRD patterns.    
 
2.3.7 Drug Loading and Entrapment Efficiency Measurement 
 
Drug loading was determined by solubilizing specific quantities of the different 
formulations in 50 ml acetonitrile, followed by sonication for 10 min to ensure  complete 
dissolution of the drug in the solvent, and then LTZ concentration was measured via 
UPLC (Waters Co., USA) using the same parameters explained in UPLC validation 
previously. The determination of drug entrapment efficiency was carried out by 
dispersing certain amounts of the different formulations in 2 ml distilled water, and then 
centrifuging at 14,800 rpm, -5°C for 1 h. The concentration of LTZ in the supernatant 
was measured by UPLC and was subtracted from its corresponding initial LTZ 
concentration used to calculate the drug loading. The concentration of LTZ in the pellets 
was also measured to ensure the accuracy of determining the entrapment efficiency using 
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the supernatant subtraction from the initial concentration of LTZ. All experiments were 
conducted in triplicates for each formulation and the mean values were recorded.   
        
2.4 In Vitro Drug Release Study and Kinetic Modeling  
 
The design of an appropriate in vitro drug release study started with the selection of a 
suitable diffusion medium that would maintain a sink condition, while ensuring the 
stability of the drug throughout the study period. The sink condition refers to the volume 
of the diffusion medium that is at least larger than 3 times the volume required to 
generate a saturated solution of the drug (140). Therefore, a solubility study was 
conducted in order to determine the required volume of the medium for the drug release 
study. This was done by solubilizing 100 mg LTZ in 20 ml 0.1 M phosphate buffer 
solution (pH 6.8) with 20% v/v Transcutol®. This solution was placed in a Julabo SW22 
shaking water bath (JULABO Labortechnik GmbH, Seelbach, Germany) at 37±1°C, 100 
rotations per min for 3 days. After that, the solution was filtered using 0.2 µm PTFE 
filters, and then injected in the UPLC system to measure the concentration of LTZ which 
reflected its solubility in the medium. The solution was then left in the shaking water bath 
for 31 days at the same previous conditions in order to ensure that LTZ remained stable 
in the medium at the end of the study period. Thus, after 31 days, the solution was again 
filtered using 0.2 µm PTFE filters, and then injected in the UPLC system to measure the 
concentration of LTZ. The difference between the concentration of LTZ after 3 days and 
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that after 31 days gave an indication about the percentage of degradation that LTZ might 
have undergone. 
In vitro release study was completed through the use of dialysis tubing cellulose 
membranes (MW cut-off= 14,000). Quantities of the optimized formulations having an 
amount of 75 mg LTZ were suspended in 10 ml of the diffusion medium and filled in the 
dialysis tubes that were then sealed with their specified closures. The tubes were then 
immersed in closed glass containers filled with 200 ml of the diffusion medium. These 
containers were placed in the shaking water bath at 37±1°C, 100 rotations per min for one 
month. At specific intervals, 5 ml was withdrawn from the external medium, filtered, and 
injected in UPLC for analysis. Similar volumes of fresh medium were used for 
replacement to maintain sufficient sink conditions. The concentrations of LTZ in the 
withdrawn medium were measured via UPLC as described previously. Cumulative 
percentage of drug release was calculated by summing the concentration of LTZ released 
at each time interval with the previous ones, and then dividing the total concentration by 
the initial drug loading used at the beginning of the experiment. Data were fitted into four 
different kinetic modeling: zero-order, first order, Higuchi model, Hixson-Crowell model, 
and Korsemeyer-Peppas semi-empirical model. For each model, both release rate 
constants (k) and correlation coefficients (R2) were computed via their corresponding 
equations. The model that provided R2 values closer to unity was considered the release 
order. 
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2.5 In Vitro Cytotoxicity Studies 
 
2.5.1 Culture Medium  
 
Eagle's Minimum Essential Medium (EMEM) (ATCC®) was used in culturing MCF-7 
cells which contained 1500 mg/L sodium bicarbonate, Earle's balanced salt solution, 2 
mM L-glutamine, nonessential amino acids, and 1 mM sodium pyruvate. An addition of 1 
% v/v Penicillin-Streptomycin-Amphotericin B (ATCC®) solution was added to the 
medium to prevent potential microbial growth. The final pH of both media was 
maintained at 7.4. 
 
2.5.2 Cell Culturing  
 
Frozen MCF-7 cells were thawed in a water bath at 37°C with gentle shaking for 2 min. 
MCF-7 cell suspension was resuspended in 2 ml medium, then centrifuged at 200 g (1100 
rpm) for 5 min, and supernatant was discarded. Under aseptic conditions, 1 ml of pre-
warmed medium at 37°C were added to the cells. The cells were mixed properly with the 
medium by slowly pipetting up and down, and then the cells suspension was placed into 
25 cm
2
 flask with additional 4 ml of the medium being added to the flask. The cells were 
incubated at 37°C, 5% CO2 with regular changing of the medium every 2-3 days. One 
week later, the cells were split and transferred into 75 cm
2
 flasks after they reached 90-
95% confluency. This was carried out by aspirating the media, washing with 5 ml 1X 
Dulbecco's Phosphate Buffered Saline (D-PBS), adding 3 ml 1X Trypsin-EDTA solution, 
and finally incubating the cells at 37°C, 5% CO2 for 5 min. Then, the cells suspension 
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was normalized with 3 ml medium. This was followed by centrifuging the cells 
suspensions at 200 g (1100 rpm) for 5 min, discarding supernatants, and re-suspending 
the pellets in 1 ml of pre-warmed medium. Now, these suspended pellets were cultured in 
75 cm
2
 flasks with additional 14 ml of the media and incubated at 37°C, 5% CO2. The 
medium was changed every 2-3 days until the cells became 90-95% confluent where they 
got harvested and used for cytotoxicity experiments.  
 
2.5.3 Treatment of Cells  
  
Cells that reached 90-95% confluency were seeded in 96-well plates at a density of 
10,000 cells/well and then incubated for 24 hours 37°C, 5% CO2 to enable them to 
recover and attach to the surface of the wells. Cell counting was done using a 
hemocytometer where 100 µL of each cell suspension was diluted with the specific 
medium to make up a final dilution ratio of 1:10. Approximately 10 µL of this diluted 
cell suspension was loaded in the hemocytometer and placed under the microscope where 
cells residing on the 4 corner squares were counted. Final cell count was calculated based 
on the following equation: 
 
 Final cell count/ml= 
Total number of cells counted x dilution factor x 104
4
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An appropriate volume of the medium was added to the concentrated cells suspension in 
order to yield a cell density of 10,000 cells/well. After 24 hours of incubation, cells were 
treated with 5 different concentrations of LTZ from each formulation: 10 nM, 100 nM, 1 
µM, 10 µM, and 100 µM. These solutions were prepared by mixing 350 ml of 1:5 v/v 
acetonitrile: Transcutol® with 1 g from each formulation which yielded solutions with 
final concentrations of 10 mM. After that, the solutions were diluted with appropriate 
volumes of the EMEM medium in order to get the required concentrations (10 nM, 100 
nM, 1 µM, 10 µM, and 100 µM). Cytotoxicity was evaluated using DNA staining after an 
incubation period of 48 hours of the treated cells. 
  
2.5.4  Cytotoxicity Measurement based on DNA Staining  
 
DNA staining was done via adding 12 µL of 38% v/v formaldehyde to each well of the 
treated MCF-7 cells to make up a final concentration of 3.8% v/v formaldehyde. Cells 
were left for 10 minutes under room temperature inside the hood to get fixed. Then, 
formaldehyde was removed and 100 µL of 0.1% v/v  4′,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) stain was added using DPBS as diluent. Cells were left for 
another 10 minutes inside the hood in order to achieve a successful DNA staining. This 
step was followed by replacing the DAPI stain with 100 µL of DPBS, and then measuring 
the cell count using ArrayScan™ XTI Live High Content Platform (ThermoFisher 
Scientific, NY, USA) where 25 fields were selected from each well for analysis.    
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Chapter 3: Results and Discussion 
  
3.1 Optimization of the Monodisperse Microparticles Production Process 
 
The production of monodisperse microparticles was carried out using the VOAG which is 
an instrument mainly designed to generate monodisperse micro-droplets of the solution 
injected into the system (133,134,141,142). When the solvent of the dissolved solute 
evaporates within the drying column, the solute settles down in a solid form with narrow 
particle size distribution. Using the original VOAG was very challenging since the 
instrument was inefficient in producing dried monodisperse microparticles as a final 
product following the specified instructions by the manufacturer. Operating the VOAG as 
is failed to produce any dried microparticles, leading to a yield that was almost zero. This 
was due to the fact that the instrument was suffering from several technical problems 
including an instability in the liquid pressure that builds up as a result of the liquid 
passing through the liquid feed tubes to the orifice, frequent clogging of the orifice which 
stopped the  whole production process, and inefficient drying system which made the 
collection of the particles extremely difficult.  
In order to stabilize the liquid pressure, the Teflon O-ring (0.075 mm  in thickness) that 
holds the orifice disc was replaced with a rubber O-ring (2 mm in thickness) supplied by 
Perkin Elmer Co., USA. In contrast to the thin Teflon O-ring, this thick rubber O-ring 
was able to sufficiently hold the orifice disc tightly in its place, prevent the leakage of the 
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liquid that contributes to the persistent drop in liquid pressure, and withstand several 
different solvents without being damaged or teared over long periods of use. 
Frequent clogging of the orifice was another major issue faced while dealing with the 
VOAG. The orifice used to get clogged constantly during the production process which 
resulted in massive material loss due to the removal of the orifice disc for cleaning 
purposes. Two different cleaning techniques were used to remove residual particles that 
clogged the orifice. The first technique was suggested by the manufacturer and this was 
the backflush of the orifice in which the dispersion cap was placed over the piezoelectric 
quartz with its opening being tightly closed, allowing the air to flow while keeping the 
drainage valve open (133). This procedure resulted in a buildup of pressure within the 
cap, forcing the air to flow against the orifice and carrying the particles away through the 
drainage tube. Despite the technique was used several times, the clogging problem 
remained persistent. The second technique used was soaking the orifice disc in excess 
volume of dichloromethane and place it in a bath sonicator (Branson B5510, UK) at 40 
kHz for 30 minutes. Such technique was only useful after few minutes of cleaning, so the 
instrument was run for 1-2 minutes, then another round of cleaning was required. This 
resulted in a huge loss of the solution between each cleaning session and also caused a 
damage to the orifice after a couple of cleaning sessions. More importantly, whenever the 
liquid jet was initiated after each cleaning session, more heterogeneous particles were 
generated due to changes in droplets velocities and diameters (143). Therefore, there was 
a need to find a way that eliminates the clogging of the orifice to maintain a consistent 
generation of monodisperse particles throughout the production process. The orifice disc 
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supplied by the manufacturer had a hole diameter of 20 µm, and such very small opening 
posed a high shear force against the passing solution, increasing the clogging of the 
orifice. This required the preparation of extremely dilute solutions in order to minimize 
the friction between the viscus solution and the orifice. However, this was not practical 
since large volumes of the organic solvent was required and the clogging was also 
experienced while using pure solvent during flushing the system. In addition, it was 
found out that the orifice disc was composed of two plates; a thin plate (approximately 
0.085 mm in thickness) facing the liquid flow where the actual orifice was grooved in, 
and a thick plate (0.254 mm in thickness) on top of the thin plate with a wider hole 
opening (1.27 mm in diameter) supporting it as depicted in Figure 4. 
 
 
 
Figure 4. Orifice disc assembly supplied by the manufacturer (135).  
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This kind of orifice disc assembly was another contributor to the clogging of the orifice 
where the pressure exerted by the passing solution caused the orifice edges within the 
thin plate to bend over and get inside the wider opening of the above thick plate. Thus, it 
was more reasonable to replace the 20-µm orifice disc originally supplied by the 
manufacturer with a specifically manufactured orifice disc to meet our production 
requirements, and this was purchased from Lenox Laser, Inc. (MD, USA) with the 
following parameters:  
Disc diameter: 9.5 mm ± 0.26% mm  
Hole diameter: 300 µm ± 5% µm 
Thickness: 0.05 mm ± 5% mm    
Centering: ± 0.25 mm 
This newly designed orifice disc consisted of only one thin plate (0.05 mm in thickness) 
where the orifice was grooved in with a diameter of 300 µm. This huge increase in orifice 
hole diameter enabled the passage of highly concentrated and viscus solutions reaching 
up to 10% w/v without any clogging experienced throughout the entire production 
process. Cleaning of the orifice was done by just wiping it off with acetone and this was 
only needed between the production of different formulations not within the same 
formulation. Hence, this new orifice disc prevented the clogging of the orifice that made 
the production process very frustrating, eliminated the necessity of cleaning while 
producing the same formulation which minimized the variation in the production 
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parameters, minimized the amount of solvent needed for cleaning, and also minimized 
the solvent used in the formulation itself.     
The final issue encountered with the use of the VOAG was the inefficient drying system  
which made the collection of the particles almost impossible. The drying column was 60 
cm in length and the dispersed droplets were supposed to be dried with the help of an air 
stream passing through the droplets at a maximum velocity of 100 L/min. The short 
length of the drying column, the rapid settling of the particles, and the absence of heat 
supply to fasten the drying process contributed all to the inefficiency in drying the 
particles. The droplets got splashed out by the air supply and settled on the side walls of 
the drying column before they dry which made them aggregate and lose their 
monodisperse properties. In an attempt to modify the drying efficiency of the VOAG, the 
air supply was replaced with a nitrogen gas supply, heating tapes set at 120 °C were 
wrapped on the external wall of the drying column as claimed to be effective in 
enhancing the drying process of the particles (141), and a vacuum attached to a collecting 
flask was mounted on the distal opening of the drying column in order to minimize 
particles collision and force them to be collected in the flask not on the side walls of the 
drying column. Unfortunately, such attempt failed to dry the particles and minimize their 
collision due to certain limitations. First, particles traveling velocity was much higher 
than that of the counteracting nitrogen gas flow and since the drying column was very 
short, the particles did not get a sufficient time to get dried. Second, the wide diameter of 
the drying column (around 20 cm) made it difficult to force the particles to line up in one 
direction, causing a more random movement of the particles, increasing their collision, 
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and ultimately residing on the side walls of the drying column. Finally, although the 
vacuum was operated at -19 Kpa, it could not pull out the particles towards the collecting 
flask due to the strong collision between the particles.       
It seemed impossible to correct the various limitations of the drying system, therefore, an 
alternative approach to collect and dry out the particles was sought without the need to 
use the drying system supplied by the manufacturer. The air supply and the drying 
column were removed, and instead, the liquid chamber base was inverted and mounted on 
a beaker where the dispersion cap was totally immersed perpendicularly in the collecting 
medium inside the beaker. The collecting medium consisted of 0.04-1% Polyvinyl 
Alcohol (PVA) aqueous solution in order to prevent agglomeration of the particles and 
effectively produce a uniform suspension of monodisperse particles. Magnetic stirring 
was used in order to prevent particles settling and facilitate solvent evaporation.  
The reduction of particle size generated from the 300-µm orifice was enabled through the 
rapid rotational movement of the collecting medium which resulted in a frictional force 
imposed on the surface of the droplets around the orifice edges. Such force was enough to 
break down the generated droplets and reduce the final particle size. Berkland et al., 
reported the use of an annular aqueous stream pumped concurrently with the organic 
stream containing the drug and the polymeric carrier in order to reduce the final particle 
size as produced by a 300-µm nozzle (144). They have reported that their system was 
able to reduce the particle size to almost 100 times smaller than the nozzle size. In our 
experiments, we were also able to produce similar results, however, it was noted that the 
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smaller the particle size achieved by this mechanism, the more heterogeneous the 
particles became, leading to a wider particle size distribution, and hence, loss of 
monodispersity. Preliminary experiments have shown that the optimal particle size 
distribution was seen with particle size of at least 15 µm, therefore no further reduction of 
the particle size was attempted.  
Several studies have reported similar problems encountered while using the VOAG in the 
production of monodisperse microparticles from different materials (134,141,142,145–
147). In these studies, different approaches have been used to overcome the limitations of 
the instrument in order to produce the intended monodisperse microparticles. Kreyling et 
al., proposed a strategy to minimize orifice clogging solution by filtering the solution 
using 0.5-µm PTFE filters; one was mounted on the syringe to filter the solution while 
being pumped, and the other one was mounted prior to the orifice disc to filter the 
solution before it passes through the orifice (148). Between the orifice disc and the Teflon 
O-ring, a metal sieve   and a spacing ring were inserted to reduce the potential of 
clogging by reducing the volume of the accumulated solution to 0.06 ml. An aqueous 
solution of 1% w/v NaCl was pumped through the VOAG to test the effectiveness of this 
strategy. Although the authors reported that the filtering strategy was capable of 
minimizing orifice clogging, the study only investigated the production of a very diluted 
salt solution which could not be of a great value when it comes to highly viscous and 
concentrated polymeric solutions. In addition, the liquid feed rate had to be limited to 2.5 
- 4 ml/h which indicated that in order to produce one gram of monodisperse solute 
particles, 25 - 40 hours would be needed. In our experiments, we were able to produce 
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similar amount of monodisperse particle in just 0.98 – 9.8 minutes. More importantly, the 
study stopped at the stage of generating monodisperse droplets without being dried and 
collected which prevents the utilization of the produced particles in beneficial 
applications.  
Soon after, Leong attempted to further enhance the performance of the VOAG by adding 
a pressure feeding system to the model suggested by Kreyling et al (143). In his trial, the 
pressure feeding system replaced the syringe pump and served as a reservoir to transport 
the solution to the orifice. However, large volumes of the solution were required to flash 
the system before actual initiation of the production process. Moreover, although the 
liquid pressure was stable with less than 3% of variation, the liquid feed rate was 
significantly different among different solutions. On top of that, the liquid feed rate had 
to be calculated appropriately before running the instrument through manual collection of 
the solution coming out of the orifice which is an inaccurate procedure. Therefore, this 
approach was difficult to adopt since it caused lots of material loss along with the 
requirement of calibration before each run.    
An interesting article was later published highlighting some new modifications made to 
overcome the reported problems of the VOAG (149). The adjustments included replacing 
the syringe pump with a pneumatic pump in order to stabilize liquid pressure along with 
replacing the acrylic drying column with a wider copper cone (0.125 m
2
 cross-sectional 
area) to minimize particle losses due to impaction. The copper cone had steep angles to 
guide the particles to be collected in one direction under gravitational force. Heating 
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tapes were also wrapped around the walls of the copper cone providing a temperature of 
20 °C to 50 °C. Despite these efforts, the authors were only able to produce smooth-
surface dried monodisperse microparticles with a maximum yield of approximately 45%. 
This was mainly due to the electrophoretic repulsion created inside the cone among the 
flowing particles, leading to their deposition on the inner walls of the cone.  
In summary, all previous attempts to optimize the use of the VOAG in generating 
monodispersed microparticles were insufficient to overcome all of its limitations. In 
contrast, the modifications we proposed in this study were successful in covering all of 
the limitations, establishing practical strategies to be implemented in order to produce the 
required monodisperse microparticles with a very high yield easily, efficiently, and in a 
timely manner.       
 
3.2 Experimental Design for Optimizing the Production Parameters  
 
In the process of generating monodisperse microparticles, the production parameters 
involved in manufacturing these particles should be studied for their effects on particle 
size distribution. This would ensure that these parameters would be set at their optimal 
values in order to produce the narrowest particles size distribution possible, which would 
result in a successful production of monodisperse microparticles. These parameters 
included drug loading, organic phase concentration, organic: aqueous phase ratio, PVA 
concentration, frequency of the vibrating orifice, liquid flow rate, and stirring rate 
(136,138,150,151). Since these parameters cannot be studied separately in which they are 
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involved in each production process, it was essential to study the effects of these 
parameters collectively in perspective of each other. Resolution 4 offered by the Placket-
Burman design permitted the estimation of the main effect of each parameter considering 
the remaining parameters using the minimal number of experiments possible with high 
accuracy (136,139,152,153). A 12-run, 2-level Placket-Burman design was created with 
each run containing a different combination of high or low levels of each 
parameter/factor as shown previously in Table 3. The different factor combinations 
resulted in a wide variation in both particle size and particle size distribution. The average 
particle size was ranging from 15.6 ± 1.1 µm to 91.6 ± 2.0 µm for PCL-based 
formulations, whereas PDLLA-based formulations had a particle size range of 22.7 ± 
0.70 µm to 99.6 ± 3.1 µm (Table 5). A huge variation in particle size distribution was 
also seen among the different formulations in which the span values ranged from 0.22 ± 
0.02 to 1.24 ± 0.27 and from 0.29 ± 0.04 to 1.48 ± 0.36 in PCL-based and PDLLA-based 
formulations, respectively (Table 5). The polydispersity nature of selected formulations 
was also noticed in SEM images as shown in Figure 5. These images represented the 
most polydisperse particles obtained from PCL- and PDLLA-based formulations. 
Particles were mostly spherical with smooth surfaces, however, there were some 
irregularly shaped and doughnut-like particles with various sizes owing to their 
polydispersity. This representation would show the difference in morphology between 
these particles generated before optimization of the factors and those generated later on 
after optimization (highlighted in next sections).  
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Table 5. Summary of the Particle Size and Particle Size Distribution Analyses for Formulations 
Run in Plackett-Burman Design 
Formulation PCL-based formulations PDLLA-based formulations 
 Mean diameter (µm) Span Mean diameter (µm) Span 
F1 47.9 ± 1.9 0.52 ± 0.03 59.2 ± 1.1 0.60 ± 0.02 
F2 47.0 ± 2.4 0.56 ± 0.03 53.3 ± 3.2 0.59 ± 0.04 
F3 33.4 ± 2.7 0.37 ± 0.03 44.0 ± 3.4 0.44 ± 0.04 
F4 58.7 ± 1.5 0.60 ± 0.02 64.0 ± 2.3 0.59 ± 0.07 
F5 15.6 ± 1.1 0.22 ± 0.02 22.7 ± 0.70 0.29 ± 0.07 
F6 91.6 ± 2.0 1.24 ± 0.27 99.6 ± 3.1 1.48 ± 0.36 
F7 47.1 ± 2.4 0.58 ± 0.04 58.0 ± 5.6 0.61 ± 0.05 
F8 57.9 ± 1.8 0.60 ± 0.04 61.1 ± 4.8 0.61 ± 0.09 
F9 61.8 ± 3.2 0.61 ± 0.05 46.6 ± 2.3 0.57 ± 0.09 
F10 76.7 ± 2.4 0.88 ± 0.03 84.2 ± 2.9 0.93 ± 0.04 
F11 17.4 ± 1.2 0.26 ± 0.04 24.0 ± 2.6 0.29 ± 0.04 
F12 88.7 ± 1.3 1.15 ± 0.22 97.8 ± 3.0 1.46 ± 0.36 
Data reported as mean ± SD, n=3. 
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Figure 5. SEM micrographs of selected formulations from Plackett-Burman design. (A): 
PCL-based formulation (F6), (B): PDLLA-based formulation (F6).  
 
A B 
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Regression analysis allowed the accurate elucidation of the effects of each 
parameter/factor on particle size distribution; span (Y) through the following equation for 
PCL-based formulations:  
Y= 0.397 - 0.00876 X1 + 0.0033 X2 + 0.0561 X3 + 4.296 X4 - 0.000273 X5 
+ 0.1983 X6 - 0.000773 X7.  
On the other hand, PDLLA-based formulations had a different equation, but with a 
similar pattern to these observed in PCL-based formulations. The equation illustrating the 
effects of each parameter/factor on particle size distribution; span (Y) for PDLLA-based 
formulations was:    
Y= 0.169 - 0.00724 X1 + 0.0211 X2 + 0.0786 X3 + 6.26 X4 – 0.000338 X5 + 0.2505 X6 
– 0.000702 X7. 
These equations were very accurate in predicting the span values for each formulation 
through setting the parameters/factors at their optimal levels to ensure achieving the 
lowest span values possible before running the experiment. This is due to the strong 
correlation between the predicted and observed span values using these equations where 
the correlation coefficient (R
2
) was 0.9668 and 0.9521 for PCL- and PDLLA-based 
formulations, respectively (Figures 6 and 7). This facilitated the production of 
formulations with narrow particle size distribution using either polymer with just few 
selections of the parameter values. 
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Figure 6. Correlation between observed and predicted span values by the model for 
PCL-based formulations. 
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One-way ANOVA analyses had revealed that all production parameters had a significant 
effect on particle size distribution (p< 0.05), except for organic phase concentration (P= 
0.955) in PCL-based formulations (Table 6). However, drug loading, organic phase 
concentration, and stirring rate were found to have no significant impact on particle size 
distribution when PDLLA was used (Table 6). This interesting observation was also 
noted previously when different polymeric carriers were used owing to the differences in 
their intrinsic characteristics (79,136–139,150–157).  
Figure 7. Correlation between observed and predicted span values by the model for 
PDLLA-based formulations.  
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Coefficient values indicated that some of the parameters had a positive relationship with 
the span, meaning which the increase in these parameters led to the increase in the span. 
These included: organic phase concentration, organic: aqueous phase ratio, PVA 
concentration, and liquid flow rate. In contrast, the other parameters had an inverse 
relationship with the span, meaning which the increase in these parameters caused a 
reduction in the span, which was favorable. These included drug loading, frequency of 
the vibrating orifice, and stirring rate. Such findings were also in agreement with other 
reports (136,137).             
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There was a general agreement between PCL- and PDLLA-based formulations in terms 
of the order of the production parameters affecting their particle size distribution. For 
PCL-based formulations, the order of the parameters from those with highest impact to 
those with lowest impact was:  
Table 6. Statistical Analysis of the Effects of the Different Production Factors on Particle Size 
Distribution as Expressed in Span 
 PCL-based formulations  PDLLA-based formulations  
Factor Coefficient p-value Coefficient p-value 
Drug loading  -0.1094 0.017 -0.0906 0.086 
Organic phase concentration  0.0017 0.955 0.0106 0.804 
Organic: aqueous phase ratio 0.1122 0.015 0.1572 0.017 
PVA concentration  0.1289 0.009 0.1878 0.009 
Frequency   -0.1228 0.011 -0.1522 0.019 
Liquid flow rate  0.1517 0.005 0.1917 0.009 
Stirring rate  -0.0967 0.025 -0.0878 0.093 
One-way ANOVA test was used, n= 3. 
The mean of the triplicates has been used to compute the coefficient and p-values for each factor. 
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Liquid flow rate > PVA concentration > Frequency of the vibrating orifice > Organic: 
aqueous phase ratio > Drug loading > Stirring rate > Organic phase concentration (Figure 
8).  
On the other hand, in PDLLA-based formulations, the order of the parameters was: 
Liquid flow rate > PVA concentration > Organic: aqueous phase ratio > Frequency of the 
vibrating orifice  > Drug loading > Stirring rate > Organic phase concentration (Figure 8). 
This indicated that there was a minor difference between the two polymers in terms of the 
parameters affecting their particle size distribution. However, it would be more 
appropriate to consider each polymeric carrier  independently during the production 
process in order to achieve optimal results.    
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A 
B 
Figure 8. Pareto chart for the different production factors affecting particle size distribution 
as expressed in span.  
(A): PCL-based formulations, (B): PDLLA-based formulations. The higher the length of the 
bars, the more effect the factor has on span. Bars crossing p-value= 0.05 indicate statistical 
significance. 
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Generally, the increase in drug loading caused a decrease in the span due to the 
subsequent increase in the viscosity of the dispersing particles. This was attributed to the 
fact that the content of LTZ increased in relation to the polymer (PCL or PDLLA) with 
higher drug loadings, causing a net increase in the overall viscosity of the formulation. As 
such, during partitioning to the external aqueous phase, more viscous organic droplets 
tend to resist the applied stirring forces as compared to the opposed dilute organic 
droplets, making them maintain their shape, size, and homogeneity (158–164). In 
contrast, the increase in organic: aqueous phase ratio led to an increased span. This was 
because the larger volume of aqueous external phase relative to the organic phase induced 
higher potential of agglomeration between the partitioning particles, resulting in non-
uniform droplets, and consequently polydisperse particles (137).  
The use of PVA was crucial in producing stably suspended droplets during the 
emulsification process. However, the concentration of PVA should be determined 
carefully since lower concentrations than required produce agglomerated particles, 
whereas higher concentrations, on the other hand, increase the external resistive forces 
against the droplets being emulsified (146). This what was exactly observed in this study 
where the lowest span achieved was obtained with PVA concentrations of 0.04% w/v, 
and the highest span was obtained with PVA concentrations of 0.1% w/v.  
The frequency of the vibrating orifice was significantly impacting the particle size 
distribution. Higher frequency tend to be more effective in generating monodisperse 
microparticles. This was mainly to due to the intensive forces applied on the emerging 
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droplets from the VOAG, which produced smaller particles that were easier to get 
homogenously dispersed than larger counterparts (144). 
Similarly, liquid flow rate, determining how much the VOAG received from the organic 
phase to generate the microparticles had also a significant effect on the span. This was 
anticipated since larger volumes supplied per unit time would produce larger particles 
that were less likely to get uniformly dispersed within the aqueous phase, leaving the 
span at its highest values (165).       
Finally, higher stirring rates were more efficient in maintaining an adequately stable 
dispersion of the droplets, leading to narrower particle size distribution (166).  
Figures 9, 10, and 11 summarized the effects of each parameter on the span in three-
dimensional schemes.              
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In a nutshell, according to the composite statistical analyses of the Plackett-Burman 
design, the optimal production parameters were identified by the model as shown in 
Table 7. These parameters were set at their specified levels for further experiments. In 
some experiments, however, different drug loading percentages were used in order to 
examine their effects on certain outcomes as would be discussed in the upcoming 
sections.           
 
 
 
 
 
 
Table 7. Recommended Values of the Different Production Factors for Yielding the Optimal 
Particle Size Distribution as Suggested by the Model Generated from Plackett-Burman Design 
Factor  Optimal value  
Drug loading  30 %w/w  
Organic phase concentration  1 %w/v 
Organic: aqueous phase ratio  1:4 
PVA concentration  0.04 %w/v 
Frequency 1000 KHz 
Liquid flow rate  0.17 ml/sec 
Stirring rate  500 rpm  
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3.3 Ultra-Performance Liquid Chromatography (UPLC) Validation  
 
In this study, we reported a simple, accurate, and precise method for analyzing LTZ from 
its pharmaceutical preparations using UPLC system. As compared with other analytical 
procedures reported in literature (167–172), the use of UPLC in this method offers more 
sensitivity, accuracy, and precision than UV spectrophotometric analyses (173), in 
addition to the advantage of withstanding higher pressure levels as opposed to High 
Performance Liquid Chromatography (HPLC) (174). Our method was able to provide a 
complete quantification of a sample within approximately 2 minutes, which is much more 
rapid than other reported methods in literature where the fastest method required a 
minimum of 10 minutes per sample (175). Therefore, the presenting method would offer 
a reliable, quick, and accurate strategy for analyzing LTZ during the development of new 
dosage forms, and as such, would be very useful and practical for research and 
development purposes.    
 
 
3.3.1 UPLC Specifications 
 
Quantification was carried out using UV at λ= 240 nm as it has been shown to be the 
most appropriate wavelength for accurately detecting LTZ (167,170,175). During the 
development of the analytical method, different ratios of acetonitrile: water was used as a 
mobile phase. It was found that an isocratic solution of 35:65 v/v (acetonitrile: water) 
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constituted the optimal ratio for extracting LTZ from its formulations. Therefore, it was 
used for subsequent analyses. The flow rate was also optimized at 0.3 ml/min.    
 
3.3.2 System Suitability 
 
It was important to ensure the developed method of analysis would be appropriate for 
detecting LTZ from its pharmaceutical formulations. Therefore, peak area, tailing factor, 
retention time, and theoretical plates were quantified in order to achieve this objective. A 
total of 6 samples were injected into the UPLC system, and their mean and relative 
standard error (RSD) were calculated and summarized in Table 8. It can be seen that 
mean peak area was 1105801 (RSD= 0.21; not more than 2.0), mean tailing factor was 
1.235 (between 0.8-2.0), mean retention time was 1.81 (RSD= 0.05; not more than 1), 
and mean theoretical plates were 3676.5 (not less than 2000). This provided an evidence 
that all system suitability parameters were met according to ICH guidelines, and hence, 
the method proofed to be suitable for carrying out the analyses (140,176).  
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3.3.3 Linearity 
 
Linearity was assessed through assaying LTZ standard solutions at 11 different 
concentrations ( 0.5, 1.0, 2.5, 5, 10, 25, 50, 100, 150, 200, and 250 µg/ml). Each sample 
was injected 3 times, and the average corresponding peak area obtained from UPLC was 
plotted against the respective concentration to produce a calibration curve (Figure 12). 
Table 8. Summary of the System Suitability Parameters Obtained from the Developed Method of 
Analysis 
Parameter  Mean ± SD % RSD Acceptance criteria 
Peak area 1105801 ± 2363.970 0.210 % RSD must not be more than 2.0 
Tailing factor 1.235 ± 0.014 1.134 Tailing factor must be between 0.8 -
2.0 
Retention time 
(min) 
1.810 ± 0.001 0.050 % RSD must not be more than 1.0 
Theoretical 
plates 
3676.5 ± 168.690 4.588 Theoretical plates must not be less 
than 2000 
n= 6.  
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Linear regression was computed for the resulting calibration curve. It was found that the 
calibration curve was linear with a high correlation coefficient (R
2
) of 0.9999. The 
regression equation explaining the relationship between the peak area and the 
concentration was y= 21863x – 640.58. Of note, previously reported methods of analysis 
had a narrow range of LTZ concentrations quantified in their linearity test such as 1-10 
µg/ml (170), 2-20 µg/ml (169), 1-50 µg/ml (167), and 10-100 µg/ml (172). Such narrow 
ranges would limit the analysis of samples containing higher concentration levels, and 
thus, dilution would be needed to not exceed the specified concentrations. This would not 
constitute a problem in our method of analysis as a wide range of concentrations was 
used (0.5-250 µg/ml).         
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3.3.4 Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
 
The calibration curve generated in the linearity test was used to calculate the LOD and 
LOQ. The SD of the residuals of the regression line was multiplied by 3.3 and 10 then 
divided by the slope to compute the LOD and LOQ, respectively. It was found that the 
LOD was 2.79 µg/ml, whereas the LOQ was 8.45 µg/ml. Although these very low levels 
would offer a high sensitivity of analysis, Annapurna et al., was able to even obtain much 
Figure 12. Calibration curve of LTZ.  
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lower levels with an LOD of 0.012 µg/ml, and an LOQ of 0.043 µg/ml, and this was a big 
advantage in their study (175).  
 
3.3.5 Accuracy 
 
The percentage recovery of 3 different LTZ concentrations (40, 50, 60 µg/ml) was used 
to assess the accuracy of the method of analysis. Table 9 presents the data obtained from 
the test. Percentage recovery was very high at all tested levels ranging from 99.17% to 
99.70%, and %RSD was very low ranging from 0.2 to 1.1. This complies with the 
specifications of the ICH guidelines where percentage recovery should be within 2.0% of 
the actual amount, and %RSD should not exceed 2% (140).  
 
 
 
 
 
Table 9. Recovery Test of LTZ 
Sample   Concentration (µg/ml) % Recovery % RSD 
Spiked sample (Level 80%) 39.73 ± 0.34 99.48 ± 0.18 0.2 
Spiked sample (Level 100%) 51.53 ± 0.84 99.17 ± 0.49 0.6 
Spiked sample (Level 120%) 60.93 ± 0.34 99.70 ± 0.92 1.1 
Data reported as mean ± SD,  n= 3.  
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3.3.6 Precision 
 
Evaluation of how precise the method of analysis was had been accomplished through 
testing for intra-day and inter-day precision. Intra-day precision was done via assaying 6 
samples having the same concentration (50 µg/ml) on the same day. On the other hand, 
inter-day precision was done via assaying 6 samples having the same concentration (50 
µg/ml) on two different days. Data has shown that 98.14% and 97.53% of LTZ was 
recovered in intra-day and inter-day precision analyses, respectively. Percentage RSD did 
not exceed 2.0% for both measurements, and the difference between intra- and inter-day 
precision was only 0.61% (Table 10). This entails that the method was precise as it 
successfully met the ICH acceptance criteria (140). 
 
 
 
 
Table 10. Precision of the Method of Analysis 
Intra-day precision Inter-day precision 
Area % Recovery %RSD Area % Recovery %RSD 
 
1145319 ± 82852.3 
 
98.14 ± 1.48 
 
1.70 
 
1096742 ± 
45944.3 
 
97.53 ± 1.14 
 
0.70 
Data reported as mean ± SD, n=6.  
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3.3.7 Forced Degradation Analyses 
 
In order to perform a complete profile of the stability of LTZ, 6 standard solutions of 
LTZ (50 µg/ml) were placed under different stress conditions including acidic, basic, 
oxidative, and thermal conditions. Photo-degradation was also assessed under both UV 
and visible light. Results has shown that LTZ was most sensitive to the basic stress 
condition where 34.11% of the drug was decomposed into 5 degradation products. This 
was probably due to the hydrolytic degradation of the liable cyano-phenyl group in LTZ 
(175). Oxidation was found to be the second condition affecting the stability of LTZ as 
11.12% of the drug was degraded. Acidic medium had lesser effects on LTZ where 
98.66% of the drug was recovered. LTZ was noticed to be less likely affected by heat, 
visible light, and UV. Resistance against these conditions would make the drug maintain 
its stability under such stresses. Table 11 summarizes the results of all forced degradation 
studies which were found to be compatible with previously reported results (175). It can 
be concluded that the method of analysis was sensitive as it was able to accurately detect 
the LTZ peak with no interference with other peaks related to the degradation products as 
depicted in Figures 13, 14, 15, 16, and 17.  
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Table 11. Summary of Forced Degradation Analyses of LTZ 
Stress condition  % Degradation % Recovery  
Standard sample  - 100 
Acidic  1.34 98.66 
Basic  34.11 65.89 
Oxidative  11.12 88.88 
Thermal  0.79 99.21 
Photolysis (UV) 0.44 99.56 
Photolysis (Visible light)  0.09 99.91 
The mean of the 6 replicates has been used to compute the % recovery and % degradation.  
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Figure 13. Chromatogram of LTZ peak and purity plot under acidic degradation. 
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Figure 14. Chromatogram of LTZ peak and purity plot under basic degradation. 
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Figure 15. Chromatogram of LTZ peak and purity plot under oxidative degradation. 
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Figure 16. Chromatogram of LTZ peak and purity plot under thermal degradation. 
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Figure 17. Chromatogram of LTZ peak and purity plot under UV-photolysis.  
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Figure 18. Chromatogram of LTZ peak and purity plot under visible light degradation. 
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3.3.8 Solution Stability  
 
Two storing conditions were used to assess the stability of LTZ solutions; at room 
temperature and in refrigerator (5°C). Standard and sample solutions having LTZ 
concentrations of 50 µg/ml were stored in tightly closed unwrapped containers at room 
temperature and in refrigerator (5°C) for 48 hours. Percentage recovery was measured 
through assaying 6 samples for each storing condition at 24 and 48 hours. Table 12 
summarized the results obtained from the UPLC analysis. Samples were found to be 
stable at both storing conditions over 48 hours. Percentage recovery was not less than 
98.0% for both storing conditions at the two time points of analysis. The respective 
%RSD values were also very low (1.1-1.7%), not exceeding 2.0% at any storing 
condition and time point. This provided as evidence that LTZ solutions were stable at 
room temperature and refrigerator for 48 hours.      
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3.3.9 Effect of Filtration 
 
Two different types of filters were used to assess the changes in percentage recovery of 
LTZ standard solutions; 0.2 µm PTFE and 0.2 µm Nylon filters. A total of 7 standard 
solutions were assayed prior to and after filtration through either PTFE or Nylon filters. 
The percentage recovery did not change significantly using either filter (Table 13). The 
difference between the percentage recovery prior to filtration and after using PTFE and 
Nylon filters was only 0.6% and 0.4%, respectively. The corresponding %RSD values 
were also within the acceptable limits (not more than 2.0%) when either filter was used 
(140).  
 
 Room temperature Refrigerator (5°C) 
 24 hrs 48 hrs 24 hrs 48 hrs 
% Recovery  98.8 ± 1.35 99.4 ± 1.56 99.8 ± 0.97 99.9 ± 1.20 
% RSD  1.5 1.7 1.1 1.3 
Data reported as mean ± SD, n=6 . 
Table 12. Stability of LTZ Solutions under Two Different Storing Conditions 
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3.4 Characterization of the Optimized Polymeric Monodisperse Microparticles 
Loaded with Letrozole 
 
3.4.1 % Yield  
 
The yield of the monodisperse microparticles produced by the VOAG constituted the 
biggest challenge in this study. The persistent clogging of the orifice made it impossible 
to produce particles with a sufficient yield. Nevertheless, the implemented modifications 
of the VOAG discussed earlier resulted in a huge change in the yield from almost 0% to 
88.2- 96.1% (Table 14). The use of an aqueous medium to collect the generated droplets 
protected them from being exposed to the electrophoretic collision inside the original 
drying column of the VOAG (141) which also contributed to the very low yield and 
difficulty in collecting the particles. This was because the collision forces resulted in the 
disposition of the droplets on the walls of the drying column, thus, no monodisperse 
Table 13. Effect of the Different Filters on Percentage Recovery of LTZ 
 Prior to filtration PTFE filter Nylon filter 
% Recovery  99.2 ± 0.49 98.6 ± 0.48 98.8 ± 0.69 
% RSD  0.6 0.40 0.80 
Data reported as mean ± SD, n= 7. 
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particles were generated. In our proposed method, we combined the ability of the VOAG 
to generate monodisperse microparticles with the advantage of the efficient collection of 
particles using the dispersion-solvent evaporation technique. This enabled the production 
of monodisperse microparticles with very high yield in an easy manner. This was 
considered a huge achievement since such high yield percentages have never been 
reported previously using the VOAG (134,141,142,145–147,177,178). The maximum 
yield obtained from the VOAG that was reported in literature was only 45% (149). This 
reflects the how much this study added to the current literature in terms of enhancing the 
efficacy of the VOAG and turning it from an instrument capable of only producing 
monodisperse stream of liquid droplets into dried monodisperse microparticles of various 
applications and uses.  
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Table 14. Summary of the Percentage Yield of the Monodisperse Microparticles Obtained 
Using the VOAG 
Sample/Formulation  % Yield (Before optimization) % Yield (After optimization) 
LTZ - 88.2 ± 1.1 
PCL - 92.3 ± 1.5 
PCL 5% LTZ  - 93.5 ± 2.6 
PCL 10% LTZ  - 96.1 ± 0.9 
PCL 20% LTZ  - 92.2 ± 2.2 
PCL 25% LTZ  - 92.3 ± 2.6 
PCL 30% LTZ  - 90.4 ± 0.2 
PDLLA  - 94.4 ± 0.3 
PDLLA 5% LTZ  - 95.2 ± 4.1 
PDLLA 10% LTZ  - 93.2 ± 3.2 
PDLLA 20% LTZ  - 94.0 ± 4.0 
PDLLA 25% LTZ  - 90.4 ± 0.4 
PDLLA 30% LTZ  - 94.2 ± 2.8 
Data presented as mean ± SD, n=3.  
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3.4.2 Morphological Analysis  
 
Using SEM, the optimized formulations using either PCL or PDLLA as a carrier 
appeared to be completely spherical in shape with fine smooth surfaces, regardless of 
LTZ concentration in the formulation (Figures 19 and 20). All particles seemed to be 
extremely uniform in size and dimensions, reflecting the high degree of monodispersity. 
Particles with lower LTZ loading (5%) were smaller than those with higher LTZ loading 
(30%) and this was normal due to the increase in their viscosity and apparent volume 
(163). Agglomeration of particles was not detected in all formulations, indicating that the 
PVA concentration was sufficient to provide adequate homogeneous dispersion of the 
particles. Similar morphology was reported previously with those succeeded in producing 
highly monodisperse microparticles (120,179–181).  
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Figure 19. SEM micrographs of optimized PCL-based formulations. (A): PCL 5% LTZ, (B): 
PCL 30% LTZ.  
 
A B 
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Figure 20. SEM micrographs of optimized PDLLA-based formulations. (A): PDLLA 5% LTZ, 
(B): PDLLA 30% LTZ.  
A B 
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3.4.3 Particle Size Analysis  
 
Solidified monodisperse microparticles were formed when the organic solvent partitioned 
to the external aqueous medium with subsequent evaporation through stirring, leaving the 
microparticles in the aqueous phase to be extracted via filtration and dried thereafter 
(182). The median particle size increased from 10.9 ± 0.21 µm to 24.7 ± 0.82 µm when 
LTZ loading was increased from 0% to 30% in PCL-based formulations (Table 15). 
Likewise, there was an increase in median particle size from 12.9 ± 0.49 µm to 27.3 ± 
0.87 µm when LTZ loading was increased from 0% to 30% in PDLLA-based 
formulations (Table 15). This significant increase in particle size (P< 0.05) might be 
attributed to the increase in organic phase concentration which produced a more viscous 
solution that was more resistant to the force applied by the stirring that broke up the large 
droplets into smaller ones (183). However, there was no significant difference between 
the particle size of PCL- and PDLLA-based formulations that had similar LTZ loadings. 
Similarly, particle size distribution showed a comparable pattern in which the span 
decreased with the increase in LTZ concentration in the formulations (Table 15). 
Although the difference between the span values did not reach statistical significance, it 
could be also related to the fact that the more viscous the organic phase became with the 
additional LTZ content, the more difficult the droplets got affected by the resistive forces 
of stirring, which maintained their original size and shape, resulting in narrower particle 
size distribution (184). Size analysis findings came in agreement with what was 
previously observed with SEM analysis, confirming the successful production of 
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monodisperse microparticles (Figures 19 and 20). In comparison to the previous studies 
which reported the production of LTZ formulations with polydisperse particles (76,89), 
our formulations had much narrower particle size distribution ranging from 0.162 ± 0.01 to  
0.195 ± 0.01 which was comparable to that of standard polystyrene monodisperse 
microparticles (span= 0.167 ± 0.02) manufacture by Sigma-Aldrich Co. LLC (Germany). 
This indicated that we were successful in producing the intended monodisperse 
microparticles which demonstrated for long an advantage over the polydisperse 
counterparts (185). 
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3.4.4 Zeta Potential Analysis 
 
Particles surface charge measurements, also referred to as zeta potential, was negative in 
all formulations which was possibly attributed to the free ester groups of PCL and 
PDLLA that constitute the outer layer of the microparticles (Table 16). This had been 
 
 
 
Formulation  Median diameter (µm) Span 
PCL 
10.9 ± 0.21* 0.171 ± 0.002 
PCL 5% LTZ 
14.7 ± 0.67* 0.185 ± 0.01 
PCL 30% LTZ 
24.7 ± 0.82* 0.162 ± 0.01 
PDLLA 
12.9 ± 0.49* 0.179 ±  0.002 
PDLLA 5% LTZ 
16.3 ± 1.1* 0.195 ± 0.01 
PDLLA 30% LTZ 
27.3 ± 0.87* 0.178 ± 0.01 
Polystyrene monodisperse 
microparticles (Control) 
23.4 ± 2.50 0.167 ± 0.02 
Data presented as mean ± SD, n=3. 
(*): Indicates statistical significance at P= 0.05 between same polymer-based groups. 
Table 15. Summary of the Particle Size and Particle Size Distribution Analyses for Optimized 
Formulations 
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stated previously by Mandal et al., who reported negative zeta potential values when 
incorporating LTZ in Poly (Lactide-co-Glycolide) nanoparticles (186). When KCL 
solution was used as dispersant instead of distilled water, there was a significant decrease 
in the zeta potential by 3-5 absolute digits. This is due to the fact that free ions of KCL 
had neutralized some of the charges of the floating particles (187,188). A significant 
decrease in the absolute value of zeta potential was observed with the increase in LTZ 
concentration as opposed to the pattern seen with particle size. Such observation could be 
explained by the fact that zeta potential is affected by the rate of particles movement in 
the system in which particles travelling slowly tend to have a decrease in the zeta 
potential, whereas those moving rapidly tend to have higher zeta potential values, 
irrespective of the charge type (i.e. negative or positive). Larger particles which are likely 
to move slowly within the system had much lower absolute zeta potential values than 
those which are smaller in size (189).     
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Table 16. Summary of the Zeta potential Analysis Using Two Different Dispersants for LTZ, PCL, 
PDLLA, and the Different Formulations 
Sample/Formulation   Zeta potential (mV) in distilled 
water 
Zeta potential (mV) in KCl 
aqueous solution 
LTZ -20.4 ± 0.5 -14.6 ± 0.5 * 
PCL -32.8 ± 1.4 -26.5 ± 1.2 
PCL 5% LTZ  -26.4 ± 0.8 -23.5 ± 0.4 
PCL 10% LTZ  -24.6 ± 0.4 -20.6 ± 0.6 * 
PCL 20% LTZ  -21.2 ± 0.7 -17.9 ± 0.2 * 
PCL 25% LTZ  -18.6 ± 0.3 -14.9 ± 0.3 * 
PCL 30% LTZ  -14.8 ± 0.3 -11.1 ± 0.2 * 
PDLLA  -31.1 ±  1.9 -24.8 ± 0.2 * 
PDLLA 5% LTZ  -27.3 ± 0.4 -23.0 ± 0.2 * 
PDLLA 10% LTZ  -24.3 ± 0.4 -21.0 ± 0.4 * 
PDLLA 20% LTZ  -22.1 ± 0.3 -18.2 ± 0.4 * 
PDLLA 25% LTZ  -19.4 ± 0.7 -15.8 ± 0.5 * 
PDLLA 30% LTZ  -15.9 ± 0.5 -12.6 ± 0.5 * 
Data presented as mean ± SD, n=3, number of measurements for each n= 15.  
(*): Indicates statistical significance at P <0.05. 
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3.4.5 Thermal Properties  
 
 DSC thermograms of pure LTZ indicated its crystalline nature with a melting point at 
186 
°
C, while PDLLA was confirmed to be amorphous with no melting point peak. On 
the other hand, PCL was confirmed to be crystalline with a melting point of 63.5 °C. The 
physical mixture of LTZ and PCL or PDLLA had significantly reduced its crystallinity 
(Tables 17 and 18, and Figures 21 and 23). The incorporation of LTZ into PCL or 
PDLLA  in the formulation resulted in a conversion of its crystalline form into an 
amorphous form where the melting point disappeared from all formulations (Tables 17 
and 18, and Figures 22 and 24).  
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Table 17. Thermal Properties of LTZ, PDLLA, and the Different Formulations with their 
Physical Mixtures 
 
Polymer 
properties 
LTZ properties 
Material 
Tg 
(°C) 
∆H 
(J/g) 
Tm (°C) ∆H (J/g) % Crystallinity 
LTZ - - 186.0 105.4 100% 
PDLLA 60.5 11.5 - - - 
PDLLA 5% LTZ (physical mix) 60.1 10.8 184.1 0.1 0.09% 
PDLLA 10% LTZ (physical mix) 59.3 11.0 184.1 0.6 0.57% 
PDLLA 20% LTZ (physical mix) 61.4 7.1 186.8 2.3 2.18% 
PDLLA 25% LTZ (physical mix) 61.2 8.1 187.6 5.3 5.03% 
PDLLA 30% LTZ (physical mix) 59.7 8.2 185.6 5.7 5.41% 
PDLLA 5% LTZ (formulation) 57.0 2.1 - - 0% 
PDLLA 10% LTZ (formulation) 50.2 2.3 - - 0% 
PDLLA 20% LTZ (formulation) 53.2 1.8 - - 0% 
PDLLA 25% LTZ (formulation) 51.9 0.9 - - 0% 
PDLLA 30% LTZ (formulation) 52.4 2.7 - - 0% 
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 Polymer properties LTZ properties 
Material Tm (°C) ∆H (J/g) Tm (°C) ∆H (J/g) % Crystallinity 
LTZ - - 186.0 105.42 100% 
PCL 63.5 48.1 - - - 
PCL 5% LTZ (physical mix) 64.6 68.7 190.5 0.5 0.47% 
PCL 10% LTZ (physical mix) 63.7 51.7 186.8 0.7 0.66% 
PCL 20% LTZ (physical mix) 64.4 37.7 187.9 1.3 1.23% 
PCL 25% LTZ (physical mix) 62.2 46.6 184.9 2.9 2.75% 
PCL 30% LTZ (physical mix) 64.1 37.2 188.0 8.3 7.87% 
PCL 5% LTZ (formulation) 57.8 34.2 - - 0% 
PCL 10% LTZ (formulation) 56.1 29.6 - - 
0% 
PCL 20% LTZ (formulation) 58.6 39.1 - - 
0% 
PCL 25% LTZ (formulation) 57.9 39.9 - - 
0% 
PCL 30% LTZ (formulation) 60.3 41.6 - - 
0% 
Table 18. Thermal Properties of LTZ, PCL, and the Different Formulations with their Physical Mixtures 
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Figure 21. DSC thermograms of LTZ, PDLLA, and their physical mixtures.  
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Figure 22. DSC thermograms of LTZ, PDLLA, and their formulations.  
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Figure 23. DSC thermograms of LTZ, PCL, and their physical mixtures.  
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Figure 24. DSC thermograms of LTZ, PCL, and their formulations.  
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3.4.6 Structural Characterization 
 
XRD analysis, however, showed some dissimilarities to those observed with DSC. As a 
more powerful technique in elucidating the physical structure of materials, XRD was able 
to show some of the distinctive peaks of LTZ crystals in PDLLA-based formulations 
containing 20%, 25%, and 30% LTZ (Figures 25 and 26). This could be possibly 
attributed to some drug crystals lying on top of particle surfaces. Although drug 
entrapment efficiency was higher in these formulations as compared to the one having 
only 5-10% LTZ, these proposed drug crystals on the surface of particles might indicate 
that the drug concentration exceeded its solubility in the polymeric matrix, leaving some 
particles in their crystalline form near or on the top of the surface (190). On the other 
hand, LTZ was found to be totally amorphous in all PCL-based formulations (Figures 27 
and 28), and this is may be due to its high hydrophobic nature (191). Of note, some of 
LTZ peaks were overlapping together which was not reported previously in literature 
(192), and this was mainly due to some technical issues found in our XRD instrument.  
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Figure 25. XRD patterns of LTZ, PDLLA and their physical mixtures.  
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Figure 26. XRD patterns of LTZ, PDLLA and their formulations.  
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 Figure 27. XRD patterns of LTZ, PCL and their physical mixtures.  
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Figure 28. XRD patterns of LTZ, PCL, and their formulations.  
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3.4.7 Drug Loading and Entrapment Efficiency Measurement   
 
Drug loading approached 100% (98.1 to 99.3%) in all formulations, indicating that the 
preparation process was effective in maintaining the intended drug content, with 
negligible drug losses during production (Table 19). Importantly, the entrapment 
efficiency which reflected the actual amount of drug encapsulated within the polymeric 
carrier was very high, ranging from 89.9% to 94.1% in PDLLA-based formulations when 
using LTZ concentrations of 5% to 30%, respectively (Table 19). Similarly, the 
entrapment efficiency was increased from 92.4% to 96.8% in PCL-based formulations 
when using LTZ concentrations of 5% to 30%, respectively (Table 19). This increase in 
entrapment efficiency with the increase in LTZ concentration could be related to the 
increase in particle size which offered smaller surface area exposed to the outer aqueous 
phase, hence greater drug proportions were successfully accommodated by the particles. 
As such, the diffusion of the drug to the aqueous medium would be much lower as 
compared to that of particles with smaller sizes and larger surface areas. Previous studies 
have shown that larger particles may have lower affinity to the aqueous medium, 
preserving more drug within the polymeric shell than smaller ones (89). Analysis of LTZ 
concentrations in the supernatants came in agreement with those measured in pellets, 
confirming the accurate measurement of entrapment efficiency in this study (Figure 29).    
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Table 19. Summary of the Drug Loading and Entrapment Efficiency Analyses for the Different Formulations 
Formulation  Drug loading 
(%) 
Entrapment efficiency 
(pellet analysis) (%) 
Entrapment efficiency 
(supernatant analysis) (%) 
PCL 5% LTZ 99.1 ± 0.04 92.4 ± 0.25 92.2 ± 0.08 
PCL 30% LTZ 99.3 ± 0.27 96.8 ± 0.06 96.2 ± 0.06 
PDLLA 5% LTZ 98.1 ± 0.26 89.9 ± 0.08 90.0 ± 0.05 
PDLLA 30% LTZ 98.6 ± 0.21 94.1 ± 0.32 93.9 ± 0.13 
P-value  0.013 <0.001 <0.001 
Reported data represents the mean ± SD, n=3. 
P-values represented the differences between the 4 formulations in terms of drug loading and entrapment efficiency.  
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3.5 In Vitro Drug Release Study and Kinetic Modeling 
  
Prior to conducting the release study, it was important to determine an appropriate 
diffusion medium that would provide a sink condition along with maintaining the 
stability of the drug over the study period. If phosphate buffer were to be used alone as a 
diffusion medium, large volumes of the medium would have been needed to establish the 
sink condition since we found that the solubility of LTZ in phosphate buffer was just 40.8 
Figure 29. Difference between entrapment efficiency analysis obtained from two different methods. 
Bars represent the average entrapment efficiency expressed as percentage. Data reported as mean ± 
SD, n=3. 
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± 5.2 µg/ml. Therefore, it was important to add a co-solvent to the phosphate buffer in 
order to enhance the solubility of LTZ, and as such minimize the required volumes of the 
medium (193). In preliminary experiments, different co-solvents were tried such as 
Tween 20, Tween 80, and Transcutol®. It was observed that Tween 20 and Tween 80 
were constantly producing air bubbles within the medium and this was a critical problem 
if they were to be used in the release study as they would form a barrier to the release of 
the drug from the diffusion membrane. Therefore, Transcutol® which only produced few 
air bubbles that were removed easily was the best choice. Different concentrations of 
Transcutol® were also tried to determine the lowest concentration possible that would 
establish the sink condition with the minimal volumes of the diffusion medium. We 
found that 20% v/v Transcutol® in phosphate buffer would satisfy our aim where the 
solubility of LTZ in this medium was found to be 204.24 ± 0.45 µg/ml (Table 20). This 
indicated that with just adding 20% v/v Transcutol® to the phosphate buffer, the 
solubility of LTZ was increased to 5 times that of the phosphate buffer alone. As such, 
the use of 210 ml of the medium would be sufficient enough to maintain the sink 
condition with the replacement of the withdrawn medium. The stability of LTZ was also 
found to be preserved where the percentage of LTZ degradation in the diffusion medium 
was only 1.2% which was lying within the acceptable range (Table 20) (140).               
In vitro drug release study was conducted to explore the drug’s behavior and the ability of 
the produced formulations to provide controlled release of LTZ. These studies have been 
used to predict the biodistribution of the drug in vivo (194). The 4 different formulations 
(PCL 5% LTZ, PCL 30% LTZ, PDLLA 5% LTZ, and PDLLA 30% LTZ) were tested for 
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drug release pattern using dialysis membranes in phosphate buffer solution (pH 6.8) 
containing 20% v/v Transcutol®. Sampling was done over one month period to obtain a 
comprehensive drug release profile since previous studies were limited to shorter periods 
of time (89,98,101,195), and our objective was to produce formulations that can be used 
for monthly administration. Figure 30 represents the cumulative percentage of drug 
released over time for the 4 formulations. It can be clearly seen that the release of LTZ 
was very slow in which 52.7%, 93%, 35.2%, and 85.4% of the drug was not released 
until after 30 days from PCL 5% LTZ, PCL 30% LTZ, PDLLA 5% LTZ, and PDLLA 
30% LTZ, respectively. Notably, the overall release rate of LTZ increased in 
correspondence to the increase in its loading and entrapment efficiency within the 
formulation where particles with 30% LTZ content displayed the highest release rates, 
whereas those with 5% LTZ content exhibited the lowest release rates as evident by the 
release rate constant (k) values (Table 21). The increase in drug entrapment efficiency 
within the polymeric matrix has been reported to have an influence on drug release rate 
(89). The higher the entrapment efficiency, the higher the probability that more drug 
would accumulate either at the surface of the particle or within the particle but at close 
proximity to the solid/liquid interface rather than the deep core of the polymeric matrix. 
This is because the concentration of the drug might have exceeded its solubility in the 
polymer, resulting in coexistence of amorphous aggregates and crystals of the drug, with 
the crystals being insoluble in the matrix, protruding near the surface of the particles. 
Consequently, faster release rates have been observed. In contrast, the lower the 
entrapment efficiency, the higher the drug solubility would be in the polymeric matrix, 
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leading to the conversion of almost all the drug crystals into amorphous counterparts, 
allowing for more homogenous distribution of the drug within the matrix with the 
majority of the drug being expected to concentrate in the core of the particles and with no 
crystals likely to be near the surface. Thus, the drug release rate would be much slower. 
Interestingly, release rate was higher in PCL-based formulations as compared with 
PDLLA-based formulations that had equal drug loadings. This was mainly due to the fact 
that LTZ was totally amorphous in PCL-based formulations, whereas in PDLLA-based 
formulations, some drug crystals were present as seen previously in XRD analysis. These 
crystals were not seen in the SEM images of the microparticles, possibly due to their 
limited amount in the formulation, whilst most of the drug was efficiently dispersed in its 
amorphous form within the polymeric matrix. The high sensitivity of XRD enabled the 
detection of such trace concentrations of the drug crystals. Importantly, the extended 
release of LTZ for one month suggested the potential of these formulations for IM depot 
administration. This would constitute one dimension of our future investigations. 
Data obtained from the in vitro release study had been tested against four different kinetic 
modeling: zero-order, first order, Higuchi model, Hixson-Crowell model, and 
Korsemeyer-Peppas semi-empirical model. Release rate constants (k) and correlation 
coefficients (R
2
) of the obtained data and the corresponding kinetic models were 
computed for the three formulations and presented in Table 21. It can be seen that the 
release profiles of the three formulations were best fitted with a biphasic zero-order 
model where highest correlation coefficient (R
2
) values were obtained (Table 21). The 
first phase lasted from 0-3 days, whilst the second phase started after 3 days and 
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continued till the end of the study period (Figure 30). Each phase had distinct release rate 
constants (k) and correlation coefficients (R
2
). It was observed that during the first phase, 
there was a slight burst effect ranging from 6.0% to 7.9% which was mainly due to the 
rapid release of the drug particles on or near the surface of the polymeric shells. 
However, after 3 days, the burst effect decreased to no more than 2.4% as all drug 
particles near the surface were released and the remaining particles started to get released 
in a more controlled manner. Again, higher burst effects were noted with PCL-based 
formulations as compared with PDLLA-based formulations. This was due to the higher 
solubility of LTZ in PCL matrices as opposed to PDLLA matrices. Despite this 
observation, the burst effects observed with our formulations were much lower than those 
seen in previous studies where the burst effects in such studies were very high reaching 
more than 80% (98,195). Thus, our formulations presented a huge advantage over the 
previous formulations in which the adverse effects that might occur due to the release of 
high concentrations of LTZ would be avoided in our formulations. The production of 
formulations with biphasic zero-order release kinetics entailed that as time elapsed, 
constant amounts of LTZ were released (196). This is of high importance since these 
formulations were successful in modifying the release of LTZ from being non-linear, 
unpredictable, and inconsistent into linear, highly predictable, and consistent, which was 
the main objective of the study. 
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Day Concentration (µg/ml) % Degradation  
Day 3 204.24 ± 0.45 1.2% 
Day 31 206.18 ± 0.62 
Reported data represents the mean ± SD, n=3. 
Table 20. Solubility and Stability of LTZ in Diffusion Medium  
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Figure 30. Drug release profile from the different formulations. 
 
Figure 31. MCF-7 viable cells after 48-hrs treatment with LTZ at different concentrationsTable 21.  
Drug release kinetic modeling of the different formulations. 
Formulation Zero order First order  Higuchi Hixon-
Crowell  
Korsemeyer-Peppas 
K R2 K R2 K R2 K 
 
R2 K R2 n 
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Table 21. Drug Release Kinetic Modeling of the Different Formulations 
Formulation Zero order 
(Phase 1) 
Zero order 
(Phase 2) 
First order  Higuchi Hixon-Crowell  Korsemeyer-Peppas 
 
K  
 
R
2
 
 
K 
 
R
2
 
 
K 
 
R
2
 
 
K 
 
R
2
 
 
K 
 
R
2
 
 
K 
 
R
2
 
 
n 
PCL 5% LTZ  5927.4 0.9951 1025.7 0.9939 0.040 0.9696 2.953 0.9833 0.002 0.3457 0.576 0.8203 0.11 
PCL 30% LTZ  5104.6 0.996 1803.7 0.9955 0.115 0.8531 5.224 0.9694 -0.005 0.4623 0.563 0.8521 0.13 
PDLLA 5% LTZ   4551.8 0.9867 708.1 0.996 0.023 0.9695 1.876 0.9802 -0.002 0.5967 1.230 0.9246 0.08 
PDLLA 30% LTZ   4533.7 0.9958 1751.1 0.9938 0.089 0.8878 4.736 0.9679 -0.005 0.5533 0.549 0.8599 0.13 
The mean of the 6 replicates has been used to compute the K and R
2
 values for each model.  
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3.6 In Vitro Cytotoxicity Studies 
 
3.6.1 Cell Culturing  
 
The main objective of this study was to develop new formulations of LTZ that would 
possess controlled drug release actions in order to prevent the fluctuations of the drug’s 
levels in the plasma, producing its intended therapeutic effects with minimal adverse 
effects. LTZ was proven to be an effective agent for the treatment of ER-positive breast 
cancer in postmenopausal women as it works by inhibiting the aromatase enzyme 
responsible for the estrogen-dependent proliferation of breast cancer cells. The in vitro 
release profile testing showed that the optimized formulations developed in this study 
produced biphasic zero-order release kinetics reflecting a controlled drug release pattern. 
Therefore, the next step was to evaluate the ability of these formulations to inhibit the 
proliferation of breast cancer cells. This was achieved through in vitro testing using 
MCF-7 cell line which is a human breast cancer cell line that was reported to express the 
aromatase activity where LTZ acts on.       
Cell culturing was performed in 75 cm
2
 flasks with appropriate volumes of EMEM 
medium which was recommended by the supplier to grow the MCF-7 cells in. The cells 
were incubated at 37°C and 5% CO2. The medium was changed every 2-3 days to keep 
the cells healthy and ensure their optimal growth. An ideal confluency of 90-95% of the 
MCF-7 cells was achieved in about one week. Afterwards, the cells were seeded in 96-
well plates and incubated for 24 hours at 37°C and 5% CO2 to get the chance to settle 
down, attach to the plate surface, and be ready to receive LTZ treatment.   
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3.6.2 Cytotoxicity Measurement  
 
Optimized LTZ formulations were considered efficacious if they would produce at least 
an equivalent percentage of inhibition of cell proliferation to that of the pure form of 
LTZ. This was assessed through measuring the average number of the viable cells after 
48-hours treatment of pure LTZ and the LTZ formulations at different concentrations (10 
nM, 100 nM, 1 µM, 10 µM, and 100 µM). Untreated MCF-7 cells were used as a control 
to quantify the percentage of inhibition of cell proliferation where they were only 
incubated with medium for 48-hours. Another control group of untreated MCF-7 cells 
were only incubated with medium for just 24-hours to detect any cytotoxic effects that 
LTZ might have on the treated cells. Cells were treated with pure LTZ and LTZ 
formulations which were mixed with EMEM medium containing 1:5 v/v (acetonitrile: 
Transcutol®) to ensure complete solubility of LTZ within the medium after being 
released from the polymeric shell, while preserving the polymeric carriers intact. The 
ratio was selected based on preliminary experiments where different ratios of different 
solvents were tried till reaching this optimal solubility with these specific solvents at 
these specific ratios. This was an important step to ensure an appropriate cellular uptake 
of LTZ would be achieved. Consequently, to rule out the effects of the solvents that they 
might exert on cell viability, three control groups were made. The first one consisted of 
1:5 v/v (acetonitrile: EMEM medium), the second one consisted of 5:1 v/v (Transcutol®: 
EMEM medium), and the last one consisted of EMEM medium with 1:5 v/v (acetonitrile: 
Transcutol®). MCF-7 cells were treated with these solvents for 48-hours to examine the 
individual effects of each solvent and their combination on cell viability. The percentage 
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of each solvent was kept similar to that used for making the treatment arms of pure LTZ 
and LTZ formulations. Additionally, the effects of the polymeric carriers were also 
assessed by treating the MCF-7 cells with each polymer at a time. Similarly, these arms 
consisted of either PCL or PDLLA suspended in EMEM medium with 1:5 v/v 
(acetonitrile: Transcutol®) to mimic the conditions of the treatment arms.         
Inhibition of cell proliferation and cytotoxicity induced by LTZ was assessed using DAPI 
staining which is a powerful tool for evaluating cell death as the assay stains the nucleic 
acids of fixed cells. Complete loss of DAPI staining in the treated cells is indicative of 
cell death as dead cells undergo nuclear fragmentation. Therefore, the quantification of 
viable cells was based on the measurement of DAPI florescence signals (197). The 
average number of nuclei of viable cells was calculated using ArrayScan™ XTI Live 
High Content Platform (ThermoFisher Scientific, NY, USA) where 25 fields were 
selected from each well for analysis.    
Results revealed that Transcutol® did not have any cytotoxic effects on MCF-7 cells 
where no significant change in cell count was seen after 48-hours of Transcutol® 
treatment. The agent was also proven to be safe as a vehicle in tissue culturing in other 
published studies (198,199). On the other hand, a significant reduction in cell count was 
observed after 48-hours of acetonitrile treatment as compared with untreated cells 48-
hours post seeding (P< 0.0001), but it was not significant when compared with those 24-
hours post seeding (P= 0.07). This prominent decrease in cell count might be due to the 
significant increase in cell count after incubating the cells with the medium for 48-hours 
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which allowed them to proliferate. Therefore, acetonitrile prevented the cells from 
proliferating, but did not cause any detectable cell death. Nonetheless, the combination of 
acetonitrile and Transcutol® appeared to be successful where Transcutol® masked the 
harmful effects of acetonitrile, providing the cells with a cytocompatible vehicle that 
enabled their growth and proliferation. Likewise, both PCL and PDLLA carriers were 
found to be cytocompatible where no difference in cell count was noted after treating the 
cells with these carriers for 48-hours.   
Importantly, it was found that LTZ was able to induce a dose-dependent inhibition of cell 
proliferation where LTZ significantly resulted in 11.3%, 39.2, 48.8%, and 74.6% 
decrease in cell count as compared with the control (untreated cells; 48-hours post 
seeding) (P< 0.0001) at concentrations of 100 nM, 1 µM, 10 µM, and 100 µM, 
respectively. However, at a concentration of 10 nM, only 3.7% reduction in cell count 
was obtained which did not reach statistical significance (P= 0.088) (Figure 31). Similar 
findings were reported previously (200), however, in some other studies, LTZ was able to 
significantly inhibit cell proliferation at very low concentrations such as 1 nM (201), and 
even as low as 0.1 nM (202). This was mainly due to the fact that in these studies, MCF-7 
cells were stably transfected with the aromatase gene which significantly intensified the 
aromatase activity of the cells, leading to a higher sensitivity towards LTZ treatment at 
very low concentrations (203). Interestingly, both PCL- and PDLLA-based formulations 
caused a significant reduction in cell count from baseline (48-hours post seeding) even at 
10 nM concentration (P< 0.0001) (Figures 32-35), reflecting more potent inhibition of 
cell proliferation as compared with pure LTZ. This could be explained by the fact that 
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polymeric carriers have been shown to enhance the cellular uptake of drugs via 
endocytosis and decrease their efflux as compared with free drugs, hence, increasing the 
time available for the drug to produce its action, and eventually resulting in a greater 
efficacy of the drug (204). According to the release profile of these formulations, 8.78 
mg, 10.22 mg, 5.76 mg, and 9.51 mg of LTZ was released after 48 hours from PCL 5% 
LTZ, PCL 30% LTZ, PDLLA 5% LTZ, and PDLLA 30% LTZ formulations, 
respectively. These amounts were even exceeding the required amount of LTZ to produce 
its effects (63) (due to the slight burst effect discussed earlier) which also explains the 
reason behind obtaining better results with the four formulations used as compared with 
those obtained from pure LTZ.  
Statistical analysis using ANOVA revealed that both PCL- and PDLLA-based 
formulations displayed a dose-dependent inhibition of cell proliferation where a 
significant difference in the cell count between the different concentrations of the 
different formulations was seen. It was noted that the inhibition of cell proliferation was 
greater in PCL-based formulations than that of the corresponding PDLLA-based 
formulations. Such observation was primarily due to the higher release rates of LTZ from 
PCL-based formulations (Table 21), in addition to the higher solubility of LTZ within the 
PCL matrix as compared to that in PDLLA matrix which was evident from the XRD 
analyses (Figures 25-28).     
Interestingly, cell death was also observed after 48-hours of treatment with LTZ, PCL- 
and PDLLA-based formulations baseline (24-hours post seeding). An exact similar 
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pattern to the inhibition of cell proliferation was encountered with cell death where pure 
LTZ resulted in a dose-dependent reduction in cell count (P< 0.0001) with 7.7%, 36.7%, 
46.7% and 73.5% of cell death was achieved at concentrations of 100 nM, 1 µM, 10 µM, 
and 100 µM, respectively. However, at a concentration of 10 nM, cell death was not 
observed. Again, with PCL- and PDLLA-based formulations, cell death was significant at 
all concentrations even at 10 nM (P< 0.0001) which was mainly due to the enhanced 
cellular uptake and reduced drug efflux obtained with polymeric carriers (204). Now, the 
dose-dependent cell death achieved with PCL-based formulations was also greater than 
that of the corresponding PDLLA-based formulations. For example, at a concentration of 
10 nM, 20.5%, 23.8%, 3.7%, and 18.8% of cells died after treatment with PCL 5% LTZ, 
PCL 30% LTZ, PDLLA 5% LTZ, and PDLLA 30% LTZ, respectively. Using the highest 
concentration (100 µM), the percentage of cell death was 81.4%, 90.4%, 76.5%, and 
86.8% after treatment with PCL 5% LTZ, PCL 30% LTZ, PDLLA 5% LTZ, and PDLLA 
30% LTZ, respectively. As discussed previously, the greater percentages of cell death 
observed in PCL-based formulations were due to the higher release rates of LTZ from 
PCL-based formulations along with the higher solubility of LTZ in PCL matrix as 
compared with that in PDLLA matrix. LTZ-induced cell death was previously reported in 
a study that demonstrated that these cytotoxic effects of LTZ might be due to its ability to 
downregulate the insulin-like growth factor I receptor (IGF-IR) which was shown to have 
a big role in cell growth and survival (205).  
To our knowledge, the only study that examined the effects of LTZ on MCF-7 cells was 
the one reported by Norouzian and Azizi (101). In their study, pure form of LTZ was 
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compared with a PEGylated niosomal LTZ formulation that was developed in their lab. 
The results showed that 50% of cells died after 48-hours of treatment with 179 µM pure 
LTZ and 101 µM PEGylated niosomal LTZ formulation. This indicated that our 
formulations produced a superior performance as compared with their formulation where 
the lowest percentage of cell death achieved with our formulations was 76.5% at a 
concentration of 100 µM.    
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Figure 33. MCF-7 viable cells after 48-hrs treatment with LTZ at different concentrations. Bars 
represent the average number of nuclei of viable cells as compared with untreated controls. Cell number 
was assessed by automated quantitation of DAPI positive nuclei using ArrayScan XTI (Target 
activation module). Data presented as mean ± SD, n=3. (*): Indicates statistical significance at P <0.05 
compared to untreated cells (48-hrs post seeding). (&): Indicates statistical significance at P <0.05 
compared to untreated cells (24-hrs post seeding). 
 
 
Figure 34. MCF-7 viable cells after 48-hrs treatment with LTZ at different concentrations. Bars 
represent the average number of nuclei of viable cells as compared with untreated controls. Cell number 
was assessed by automated quantitation of DAPI positive nuclei using ArrayScan XTI (Target 
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Figure 35. MCF-7 viable cells after 48-hrs treatment with PCL 5% LTZ formulation at different 
concentrations. Bars represent the average number of nuclei of viable cells as compared with 
untreated controls and PCL. Cell number was assessed by automated quantitation of DAPI positive 
nuclei using ArrayScan XTI (Target activation module). (*): Indicates statistical significance at P 
<0.05 compared to untreated cells (48-hrs post seeding). (&): Indicates statistical significance at P 
<0.05 compared to untreated cells (24-hrs post seeding). (#): Indicates statistical significance at P 
<0.05 compared to PCL. 
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Figure 36. MCF-7 viable cells after 48-hrs treatment with PCL 30% LTZ formulation at different 
concentrations. Bars represent the average number of nuclei of viable cells as compared with untreated 
controls and PCL. Cell number was assessed by automated quantitation of DAPI positive nuclei using 
ArrayScan XTI (Target activation module). Data presented as mean ± SD, n=3. (*): Indicates statistical 
significance at P <0.05 compared to untreated cells (48-hrs post seeding). (&): Indicates statistical 
significance at P <0.05 compared to untreated cells (24-hrs post seeding). (#): Indicates statistical 
significance at P <0.05 compared to PCL. 
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Figure 37. MCF-7 viable cells after 48-hrs treatment with PDLLA 5% LTZ formulation at different 
concentrations. Bars represent the average number of nuclei of viable cells as compared with 
untreated controls and PDLLA. Cell number was assessed by automated quantitation of DAPI 
positive nuclei using ArrayScan XTI (Target activation module). Data presented as mean ± SD, n=3. 
(*): Indicates statistical significance at P <0.05 compared to untreated cells (48-hrs post seeding). (&): 
Indicates statistical significance at P <0.05 compared to untreated cells (24-hrs post seeding). (#): 
Indicates statistical significance at P <0.05 compared to PDLLA. 
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Figure 38. MCF-7 viable cells after 48-hrs treatment with PDLLA 30% LTZ formulation at different 
concentrations. Bars represent the average number of nuclei of viable cells as compared with untreated 
controls and PDLLA. Cell number was assessed by automated quantitation of DAPI positive nuclei 
using ArrayScan XTI (Target activation module). Data presented as mean ± SD, n=3. (*): Indicates 
statistical significance at P <0.05 compared to untreated cells (48-hrs post seeding). (&): Indicates 
statistical significance at P <0.05 compared to untreated cells (24-hrs post seeding). (#): Indicates 
statistical significance at P <0.05 compared to PDLLA. 
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CONCLUSION 
 
This study presented a new technique that was simple, easy, and rapid for the production 
of monodisperse microparticles which would bring advances in the drug delivery realm. 
LTZ was incorporated within either PCL or PDLLA carriers in order to optimize its non-
linear pharmacokinetic release profile, and hence, minimize the adverse effects associated 
with its use in postmenopausal women with ER-positive breast cancer. An instrument 
originally designed to produce monodisperse liquid jet, the VOAG, was exploited to 
produce the intended encapsulation of LTZ within PCL or PDLLA. Without various 
modifications implemented to the instrument, the production of monodisperse 
microparticles was enabled. Plackett-Burman design helped in further identifying the 
production parameters affecting the particle size distribution, which allowed the 
determination of the optimal values of these parameters in order to achieve the most 
monodisperse microparticles. Successfully produced monodisperse PCL- and PDLLA-
based formulations were characterized for particle size and morphology which confirmed 
their narrow size distribution. LTZ loading and entrapment efficiency were very high 
among all formulations. Importantly, in vitro dissolution studies revealed that LTZ 
release from these formulations were constant, time-independent, following zero-order 
kinetics throughout the study. In vitro cytotoxicity showed that PCL- and PDLLA-based 
formulations intensified the cytotoxic effects of LTZ on MCF-7 cells at very low 
concentrations reaching 10 nM. The findings of this study are promising as they indicated 
that such monodisperse microparticles may serve as new LTZ formulations for monthly 
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administration that offered better release profile, which may result in minimal adverse 
effects. Future studies should be directed towards covering the areas that were not 
thoroughly investigated since they were out of the scope of this study. These include 
conducting a stability indicating method to validate the use of the developed UPLC 
method in analyzing LTZ formulations containing PCL or PDLLA.  In addition, long-
term stability studies should be run for the produced formulations and their release 
profiles should also be explored after long periods of storage. Importantly, the method of 
sterilizing these formulations should be considered and the impact of the chosen method 
on drug release profiles should also be studied. To ensure the safety of the produced 
formulations, their effects on normal human breast cells should be tested. Finally, in vivo 
studies using breast cancer animal models will be vital in providing a complete picture 
about the therapeutic as well as toxic effects of the produced formulations.   
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